Substituted dipeptide amides #3

ABSTRACT

The invention relates to novel substituted tyrosyl alanine dipeptide amides of the formula: ##STR1## and the pharmaceutically acceptable acid addition salts thereof wherein R 1  is hydrogen, lower alkyl, hydroxy, --OCO 2  lower alkyl, lower alkoxy, --O(CH 2 ) n  --phenyl with the phenyl optionally substituted by halogen, --NO 2 , --CN, --NH 2  or lower alkyl wherein n is 1 to 4; R 2  and R 3  represent lower alkyl, halogen, or lower alkoxy, or either one of R 2  or R 3  is hydrogen and the other is lower alkyl, lower alkoxy or halogen; R 4 , R 5 , R 6 , R 7 , R 8 , and R 9  may be the same or different and represent hydrogen or lower alkyl; R 10  is selected from the group consisting of 
     
         --(ALK)X 
    
     where ALK represents alkylene, thioalkylene, oxyalkylene, having 1 to 5 carbon atoms; alkenylene and alkynylene having 2 to 4 carbon atoms; and X represents pyridyl, pyrimidinyl, 9H-fluoren-9-yl, diphenylmethyl, thienyl, carboxy, lower alkoxy carbonyl, substituted phenyl wherein the phenyl substituent is amino, hydroxy, halogen, nitro, methylenedioxy, lower alkyl, carboxy, lower alkoxycarbonyl, lower alkoxy, carboxamide, diloweralkylamino or X represents phenyl when ALK is not alkylene; or R 10  is ##STR2## where p and q are independently 1 to 4; or R 9  and R 10  together with N is ##STR3## where r and t are independently 1 to 4; 
     v represents an asymmetric carbon that may be racemic or have the D or L configuration; 
     w represents an asymmetric carbon when R 7  and R 8  are not the same that may be racemic or have the D or L configuration. 
     These compounds are useful as analgesic and/or antihypertensive compounds.

This application is a division of Ser. No. 882,794 filed July 14, 1986, now U.S. Pat. No. 4,822,775 which is a continuation-in-part of Ser. No. 829,266 filed February 14, 1986, now abandoned, which is a continuation-in-part of Ser. No. 765,882 filed August 14, 1985, now abandoned.

FIELD OF THE INVENTION

The present invention relates to novel dipeptide amides. In particular, it provides novel dipeptide derivatives of Formula 1 which are useful as analgesic or antihypertensive agents.

BACKGROUND OF THE INVENTION

In 1975, a pentapeptide, methionine enkephalin, was reported by Hughes et al., Nature, 258, 577 (1975). This peptide is found in many areas of the brain where it appears to act as a neurotransmitter or neuromodulator in a central pain-suppressant system. The natural peptide binds stereospecifically to partially purified brain opiate receptor sites, see for example, Bradberry et al., Nature, 260, 793 (1976). The natural peptide is also highly active in bioassays for opiate activity but exhibits only weak, fleeting analgesic activity when injected directly into the brain of the rat, see for example, Belluzi et al., Nature, 260, 625 (1976).

In order to overcome the lack of in vivo activity, a number of investigators have made numerous modifications in the methionine enkephalin structure, such as substituting the glycine in the 2-position with a D-amino acid, N-methylation of the L-tyrosine, substituting the 4-phenylalanine with, for example, methyl or halo, modifying the C-terminus, etc., to produce enkephalin derivatives of varying properties and potencies.

Kiso, et al., "Peptide Chemistry 1981,": 65-70, Protein Research Foundation, Osaka, Japan (1982), disclosed the synthesis and activity of short chain enkephalin-like peptides, among them tripeptide and dipeptide alkylamides such as N-methyl tyrosine (D) methionine sulfoxide glycine-methylphenethylamide (2) and tyrosine-(D) methionine sulfoxide phenylpropylamide (3). ##STR4## Vavrek, et al., Peptides 2, 303, 1981 disclosed analogs of enkephalin, among them the dipeptide tyrosine-D-alanine-phenylpropylamide (Tyr-(D)Ala-PPA) (4). ##STR5##

The compounds of this invention have unexpected and surprisingly superior properties when compared to the Vavrek compound. The present invention provides new dipeptide derivatives which show improved potency as analgesic agents by both oral and parenteral routes of administration. Additionally, U.S. Pat. No. 4,316,892 relates to certain derivatives of methionine enkephalin derivatives useful as analgesic agents.

SUMMARY OF THE INVENTION

This invention encompasses analgesic tyrosine derivatives of formula I: ##STR6## and the pharmaceutically acceptable acid addition salts thereof wherein R¹ is hydrogen, lower alkyl, hydroxy, --O--CO₂ lower alkyl, lower alkoxy, O(CH₂)_(n) phenyl with the phenyl optionally substituted by halogen, --NO₂, --CN, --NH₂ or lower alkyl wherein n is 1 to 4; R² and R³ represent lower alkyl, halogen, or lower alkoxy, or either one or R² or R³ is hydrogen and the other is lower alkyl, lower alkoxy or halogen; R⁴, R⁵, R⁶, R⁷, R⁸, and R⁹ may be the same or different and represent hydrogen, or lower alkyl; R¹⁰ is selected from the group consisting of

    --(ALK)X

where ALK represents alkylene, thioalkylene or oxyalkylene, having 1 to 5 carbon atoms; or alkenylene and alkynylene having 2 to 4 carbon atoms; and X represents pyridyl, pyrimidinyl, 9H-fluoren-9-yl, di-phenylmethyl, thienyl, carboxy, loweralkoxycarbonyl, substituted phenyl wherein the phenyl substituent is amino, hydroxy, halogen, nitro, methylenedioxy, lower alkyl, carboxy, lower alkoxycarbonyl, lower alkoxy carboxamide, diloweralkylamino or X represents phenyl when ALK is not alkylene; or R¹⁰ is ##STR7## where p and q are independently 1 to 4; or R⁹ and R¹⁰ together with N is ##STR8## where r and t are independently 1 to 4;

v represents an asymmetric carbon that may be racemic or have the D or L configuration;

w represents an asymmetric carbon when R⁷ and R⁸ are not the same that may be racemic or have the D or L configuration. In the context of this invention and the definition of R¹ through R¹⁰ lower alkyl means straight or branched chain alkyls having 1 to 6 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, pentyl, and isomers thereof, and hexyl and isomer thereof. Lower alkoxy means alkoxy having 1 to 6 carbon atoms where the alkyl moiety are as described above for lower alkyl. Halo refers to chloro, fluoro, bromo and iodo.

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

The compounds described in this invention are illustrated in Examples 1-182 are synthesized by either of two procedures shown in schemes 1 and 2 as Route A and Route B. Many of the compounds can be prepared by either route with the principal difference being the reaction sequence.

Route A in Scheme I and Route B in Scheme II illustrate two methods for making compounds of this invention. In Route A a blocked amino acid derivative X is reacted with a dialkylamino XI by mixed anhydride coupling and the blocking group is removed by catalytic hydrogenation to provide amide XII. A blocked tyrosine derivative XIII is reacted with amide XII by the mixed anhydride method to provide XIV which is separated into diastereomers, which are separately deblocked to provide compounds of formula I.

In Route B Scheme II the ester of the amino acid derivative is coupled with XIII by mixed anhydride coupling to provide ester XVI. This ester XVI is separated into diastereomers. For example, if XV is a D amino acid derivative and XIII is a DL tyrosine derivative, the DD and LD diastereomers are provided. The appropriate dialkylamine is then coupled to the separated diastereomer of XVII, and the product is deblocked to provide the compounds of Formula I.

In Schemes I and II Boc refers to tertiary butoxy carbonyl and R¹ through R¹⁰ are as previously defined. Z is Boc or benzyloxy. Z can be Boc in non sulfur containing X and removed by hydrolysis in hydrochloric acid in diocan.

Diastereomers are separated by standard techniques such as crystalization or column chromatography. ##STR9##

The analgesic activity for the compounds of the present invention is illustrated by their activity in the following tests. In some cases the analgesic activity of the representative compounds was compared with that of a disclosed analog of enkephalin, tyrosine-(D)-alanine-phenylpropylamide.

Writhing assay.

Male Charles River albino mice (CD-1/HAM/1LR) weighing between 20 and 30 grams were used. Thirty minutes after subcutaneous or intragastric administration of the test compound (0.1 mg/10 gram body weight), 0.025% (w/v) phenylbenzoquinone was injected intraperitoneally (0.1 ml/10 gram body weight). Five minutes later, each mouse was placed in a large glass beaker and the number of writhes that occured in the subsequent ten minutes is counted. A writhe consisted of dorsoflexion of the back, extension of the hindlimbs, and strong contraction of the abdominal musculature. The test compound was considered to have produced analgesia in a mouse if the number of writhes elicited by phenylbenzoquinone was equal to or less than one-half the median number of writhes recorded for the saline-treated group that day. The results were expressed as the number of mice (out of a possible ten) in which the test compound produced analgesia. The test compound was rated active if the number of writhes in the drug treatment group was significantly less than the number of writhes in the saline treatment group as determined by a one-way analysis of variance. If the initial test dose of 10 mg/kg inhibited writhing in greater than 6 of 10 mice, the effect of additional doses was evaluated and an ED₅₀ value was calculated using a maximum likelihood function.

Opiate Binding Assay.

The test compounds were evaluated for their ability to displace the binding of ³ H-Naloxone to opiate receptors isolated from rat brain. Male rats [Crl:CD(SD)BR] obtained from Charles River Laboratories (Portage, MI) were sacrificed by cervical dislocation. A purified homogenate of receptor membranes was prepared from the brains according to the method described by Chang and Cuatrecasas. (K.-J. Chang and P. Cuatrecasas. Multiple Opiate Receptors: Enkephalins And Morphine Bind To Receptors Of Different Specificity. J. Biol. Chem. 254, 2610-2618 (1979).) The brains were homogenized in 10 volumes of 0.32M sucrose and centrifuged twice at 6,000 xg for 15 minutes. Following centrifugation of the supernatants at 40,000 xg for 30 minutes, the pellets were resuspended in 5 mM tris HCl, and centrifuged at 6,000. The supernatant was centrifuged at 40,000 xg. The resuspension in 5 mM tris and centrifugation was repeated twice. The final pellet was resuspended in 2 volumes of 50 mM tris HCl (pH 7.4). The homogenate was assayed for protein content according to the method of Itzhaki and Gill (R. F. Itzhaki and D. M. Gill. A Micro-Biuret Method for Estimating Proteins. Anal. Biochem. 9, 401-410 (1964).)

The binding of the test compounds to the receptor membrane preparation was measured using a modification of the method of Pert and Snyder (C. B. Pert and S. H. Snyder. Properties of Opiate-Receptor Binding in Rat Brain. Proc. Natl. Acad. Sci. 70, 2243-2247 (1973).) The receptor assay was run using a final concentration of 1 nM ³ H-Naloxone and 0.5 mg/ml of homogenate protein. Levorphanol (1×10⁻⁵ M) was used as the displacer for non-specific binding. The final concentration of the test compounds was 10⁻⁵ M. The assay was run in 0.05M tris HCl (pH 7.4). Total assay volume was 1.0 ml.

Samples were incubated at 25° C. for 60 min., filtered over Whatman GF/C glass fiber filters and rinsed twice with 2.4 ml washes of ice-cold buffer. The filters were air dried at 50° C. for 30 min. After drying, 10 ml. of PCS was added to the vial and radioactivity determined using a Tracor Analytic Mark III liquid scintillation counter with a counting efficiency of 48%.

The IC₅₀ values, the concentration of the test compounds which inhibited ³ H-Naloxone specific binding to the opiate receptor by 50%, were obtained from log-logit plots of concentration-response curves.

The compounds can be administered in such oral dosage forms as tablets, capsules, pills, powders, granules, suspensions, or solutions. They may also be administered rectally or vaginally, in such forms as suppositories or bougies. They may also be introduced in the form of eyedrops, intraperitoneally, subcutaneously or intramuscularly, using forms known to the pharmaceutical art. In general the preferred form of administration is oral.

An effective but nontoxic quantity of the compound is employed in treatment. The dosage regimen for preventing or treating symptoms by the compounds of this invention is selected in accordance with a variety of factors including the type, age, weight, sex, and medical condition of the mammal, the severity of the symptoms, the route of administration of the particular compound employed. An ordinary skilled physician or veterinarian will readily determine and prescribe the effective amount based on the route of administration of the analgesic agent to prevent or arrest the progress of the condition. In so proceeding, the physician or veterinarian could employ relatively low dosages at first, subsequently increasing the dose until a maximum response is obtained.

The compounds of Formula 1 can also be administered as pharmaceutically acceptable acid addition salts such as the hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate, propionate, lactate, maleate, malate, succinate, tartrate and the like. Additionally, the compounds of this invention may be administered in a suitable hydrated form.

The compounds of this invention may be prepared by any number of methods known to those skilled in the art. For example, the particular sequence of reactions by which the individual amino acids are joined to form the compounds of Formula 1 is generally not of critical importance, being chosen principally for convenience or for maximum yields. Moreover, the choice of activating reagents and conditions for joining amino acids or small peptides is not limited to those specifically described herein. Peptide intermediates and products of this invention are typically purified by crystallization, where possible, or by column chromatography. Furthermore, where racemic amino acid starting materials are employed, intermediates and products may be separated during column chromatography into diastereomers. The accompanying examples illustrate two of the possible methods used to prepare the compounds of this invention.

ROUTE A

EXAMPLE 1 methyl 6-[[2R-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]hexanoate ##STR10## (Boc=t-butoxycarbonyl) Boc-(D)Ala-NH(CH₂)₅ CO₂ Me

Boc-(D)-alanine (5.1 g, 26.9 mmol) in 100 ml of methylene chloride (CH₂ Cl₂) was cooled to 0° C. and 5.9 ml (53.8 mmol) of N-methylmorpholine (NMM) were added. After cooling this vigorously stirred solution to -78° C., 3.5 ml (26.9 mmol) of isobutylchloroformate (IBCF) were added to this reaction which was run entirely under an Ar atmosphere. The mixture was allowed to warm slowly to 20° before it was again cooled to -78° C. and 4.9 g (26.9 mmol) of 6-aminohexanoic acid methylester hydrochloride were added in a single portion. Following warming this mixture to room temperature, it was allowed to stir 25 hour (h). Precipitated N-methylmorpholine hydrochloride was filtered off and the filtrate, after diluting with CH₂ Cl₂ (200 ml), was washed 3×100 ml of 0.5N potassium bisulfate (KHSO₄). The combined aqueous washes were extracted with a 100 ml portion of CH₂ Cl₂ and the combined organics were washed 1×75 ml of brine, dried over Na₂ SO₄ (anhy.), and stripped of all solvent under reduced pressure. By thin layer chromatography (10% ethanol (EtOH)/chloroform (CHCl₃)) the yellow liquid title product was essentially one spot and used in subsequent reactions without further purification. Optical rotation [α]_(D) +21.5° and +93.7° (365 nm) CHCl₃. NMR shift of the (D)Ala methyl=1.34δ (CDCl₃).

Analysis Calcd. for C₁₅ H₂₈ N₂ O₅ ·1/2H₂ O (MW=325.410): C, 55.36; H, 8.98; N, 8.61. Found: C, 55.82; H, 8.50; N, 8.12.

EXAMPLE 2 methyl 6-[(2R-amino-1-oxopropyl)amino]hexanoate, monohydrochloride ##STR11## (D)Ala-NH(CH₂)₅ CO₂ Me·HCl

The product of Example 1 (8.0 g, 25 mmol) was dissolved in 100 ml of acetic acid (HOAc). To this solution was added 40 ml (250 mmol) of 6.2N HCl/dioxane. This solution was then gently stirred under a nitrogen (N₂) atmosphere and at room temperature for 1 h before all solvent was removed under reduced pressure. The resulting colorless oil residue was washed liberally with diethylether (Et₂ O) before being dried under vacuum to yield 7.1 g of the title product. This material was used in subsequent experiments without further purification.

Optical rotation [α]_(D) -1.8°, -14.2° (365) MeOH.

NMR shift of the (D)Ala methyl=1.49δ (CD₃ OD).

Analysis Calcd. for C₁₀ H₂₁ N₂₁ O₃ Cl·3/4H₂ O (MW=266.26): C, 45.11; H, 8.52; N, 10.52. Found: C, 45.04; H, 8.56; N, 10.00.

EXAMPLE 3 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-O[(2-methylpropoxy)carbonyl]-DL-tyrosyl-N-(6-methoxy-6-oxohexyl)-D-alaninamide ##STR12## (CO₂ iBu=IBC) (Boc-(DL)2,6-Me₂ Tyr(IBC)-(D)Ala-NH(CH₂)₅ CO₂ Me)

Racemic t-butoxycarbonyl-2,6-dimethyltyrosine (4.0 g, 12.9 mmol) in 60 ml of CH₂ Cl₂ was cooled to 0° C. before NMM (4.3 ml, 38.8 mmol) was added in one portion. After cooling the vigorously stirred mixture, maintained under an Ar atmosphere, to -78° C., 3.4 ml (25.8 mmol) of IBCF was added. The reaction was warmed slowly to room temperature and then recooled to -78° C. To this mixture was added 3.7 g (12.9 mmol) of the title material of Example 2. The heterogeneous reaction was again allowed to warm slowly to room temperature and stir at this temperature for 18 h. After the reaction mixture was worked up as described in Example 1, the resulting 8 g of product solid was chromatographed on a Waters Prep 500 using a 50×300 mm Porasil column eluting with 2% EtOH/CH₂ Cl₂. By this procedure the two diastereomers of the title materials were isolated. The diastereomer which possesses a NMR chemical shift for its (D)Ala methyl doublet up-field from its companion diastereomer was labeled UF(up-field, smaller number). The other diastereomer having the down-field NMR chemical shift for its (D)Ala methyl was labeled DF (down-field, larger number). This nomenclature is used throughout the examples.

Diastereomer UF (2.46 g) [α]_(D) +29.7°; +35.1° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.08δ (CD₂ Cl₂).

Analysis Calcd. for C₃₁ H₄₉ N₃ O₉ (MW=607.62): C, 61.27; H, 8.13; N, 6.91. Found: C, 61.52; H, 8.25; N, 6.93.

Diastereomer DF (2.22 g) [α]_(D) 0.0°; +8.3° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.31δ (CD₂ Cl₂).

Analysis Calcd. for C₃₁ H₄₉ N₃ O₉ (MW=607.62): C, 61.27; H, 8.13; N, 6.91. Found: C, 61.50; H, 8.16; N, 6.87.

EXAMPLE 4 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyltyrosyl-N-(6-methoxy-6-oxohexyl)-D-alaninamide UF isomer ##STR13## (Boc-2,6Me₂ Tyr-(D)Ala-NH(CH₂)₅ CO₂ Me)

The UF diastereomer (δ=1.08, NMR chemical shift of the (D) alanine methyl) of Example 3 (2.37 g, 3.9 mmol) was dissolved in 40 ml of methanol (MeOH). To this solution was added 590 mg (4.3 mmol) of potassium carbonate (K₂ CO₃). The reaction vessel containing this mixture was flushed with Ar, stoppered, and stirred for 1 h before TLC (5% EtOH/CHCl₃) indicated that the reaction was complete. After diluting this mixture with 300 ml of CH₂ Cl₂ and adding 100 ml of 0.5N KHSO₄ the mixture was stirred for 14 h. The organic layer was separted and washed 2×100 ml of 0.5N KHSO₄. The combined aqueous layers were then extracted 1×75 ml of CH₂ Cl₂ before the combined organics were washed 1×100 ml of brine, dried (Na₂ SO₄), and stripped of all solvent under reduced pressure. The resultng white glass was washed extensively with hexanes (SKB) and Et₂ O combinations and dried under vacuum to give the analytically pure title product (2.0 g).

Optical rotation [α]_(D) =+47.2°; +186.0° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.08δ (CD₂ Cl₂).

Analysis Calcd. for C₂₆ H₄₁ N₃ O₇ ·1/2H₂ O (MW=516.15): C, 60.44; H, 8.19; N, 8.13. Found: C, 60.76; H, 8.13; N, 7.93.

EXAMPLE 5 2,6-dimethyltyrosyl-N-(6-methoxy-6-oxohexyl)-D-alaninamide, monohydrochloride DF isomer ##STR14## (Boc-2,6Me₂ Tyr-(D)Ala-NH(CH₂)₅ CO₂ Me)

Using the method of Example 4, 2.05 g (3.37 mmol) of the S-diastereomer of Example 3 was converted to the 1.73 g of the title product.

Optical rotation [α]_(D) -12.0°; -21.2° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.27δ (CD₂ Cl₂).

Analysis Calcd. for C₂₆ H₄₁ N₃ O₇ ·1/2H₂ O (MW=516.65): C, 60.44; H, 8.19; N, 8.13. Found: C, 60.72; H, 8.06; N, 8.00.

EXAMPLE 6 2,6-dimethyltyrosyl-N-(6-methoxy-6-oxohexyl)-D-alaninamide, monohydrochloride UF isomer ##STR15## (2,6Me₂ Tyr-(D)Ala-NH(CH₂)₅ CO₂ Me·HCl)

The product of Example 4 (1.80 g, 3.48 mmol) was dissolved in 25 ml of acetic acid (HOAc). To this solution stirred gently at room temperature under a nitrogen (N₂) atmosphere was added 6 ml of 6N HCl/dioxane. After one hour all the solvent was removed under reduced pressure and the resulting pale yellow oil was shaken with Et₂ O to produce the white solid product salt. This material was suctioned filtered, washed with Et₂ O and dried under vacuum to yield 1.6 g of the title compound. Optical rotation [α]_(D) +106.3°; +420.5° (365) MeOH.

NMR shift of the (D)Ala methyl=1.03δ (CD₃ OD).

Analysis calcd. for C₂₁ H₃₄ N₃ O₅ ·1/2H₂ O (MW=452.98); C, 55.68; H, 7.79; N, 9.28. Found: C, 55.76; H, 7.69; N, 9.26.

EXAMPLE 7 2,6-dimethyltyrosyl-N-(6-methoxy-6-oxohexyl)-D-alaninamide, monohydrochloride DF isomer ##STR16## (2,6-Me₂ Tyr-(D)Ala-NH(CH₂)₅ CO₂ Me·HCl)

The title material of Example 5 was deblocked by the method of Example 6.

Optical rotation [α]_(D) -67.0°; -238.3° (365) MeOH.

NMR shift of the (D)Ala methyl=1.28δ (CD₃ OD).

Analysis Calcd. for C₂₁ H₃₄ N₃ O₅ Cl·1/2H₂ O (MW=452.98): C, 55.68; H, 7.79; N, 9.28. Found: C, 55.33; H, 7.51; N, 9.26.

EXAMPLE 8 phenylmethyl [1R-methyl-2-oxo-2-[(tricyclo[3.3.1.1³,7 ]dec-2-yl)amino]ethyl]carbamate ##STR17## (Z-(D)Ala-NH2Ad)

The title compound was prepared by the methods of Example 1 where Z-(D)Alanine (10.0 g, 44.8 mmol) was used in place of Boc-(D)Alanine and H₂ N2Ad.HCl (8.4_(S), 44.8 mmol) was used in place of NH₂ (CH₂)₅ CO₂ Me·HCl. After workup, 17.3 g of the yellow viscous oil product was obtained and used in subsequent examples without further purification.

Optical rotation [α]_(D) +18.9°; +68.7° (589) CHCl₃.

NMR shift of the (D)Ala methyl=1.33δ (CD₂ Cl₂).

Analysis Calcd. for C₂₁ H₂₈ N₂ O₃ ·1/2H₂ O (MW=365.48): C, 69.01; H, 8.00; N, 7.66. Found: C, 68.57; H, 7.93; N, 7.06.

EXAMPLE 9 2R-amino-N-(tricyclo[3.3.1.13,7]dec-2-yl) propanamide ##STR18## ((D)Ala-NH2Ad)

The product of Example 8 above (15.8 g, 43.2 mmol) was hydrogenated in 125 ml of methanol (MeOH) over Pd black catalyst. The hydrogenation was carried out in a Parr Apparatus at room temperature under H₂ at 60 psi. There was a theoretical uptake of H₂ over a 6 hour period. The catalyst was filtered from the solution and all solvent was removed under reduced pressure to provide 7.32 g of the white solid product after washing with Et₂ O and drying under vacuum.

Optical rotation [α]_(D) -0.8°; 1.6° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.34δ (CDCl₃).

Analysis calcd. for C₁₃ H₂₂ N₂ O·1/4H₂ O (MW=226.84): C, 68.80; H, 10.00; N, 12.35. Found: C, 68.50; H, 9.86; N, 12.55.

EXAMPLE 10 Mix of Diastereomers N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-O-[(2-methylpropoxy)carbonyl]-DL-tyrosyl-N-(tricyclo[3.3.1.13,7]dec-2-yl)-D-alaninamide ##STR19## (Boc-(DL)2,6Me₂ Tyr(IBC)-(D)Ala-NH2Ad)

The title mixture of diastereomers (iso-UF & DF) was prepared as described in Example 3 using the title material of Example 9 (1.5 g, 6.5 mmol) in place of that from Example 2. Both title diastereomers were separated by pressure liquid chromatography (PLC) on Merck silica eluting with 10% ethyl acetate (EtOAc)/CH₂ Cl₂.

Diastereomer UF (1.54 g) [α]_(D) +35.2°; +145.7° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.08δ (CD₂ Cl₂).

Analysis Calcd. for C₃₄ H₅₁ N₃ O₇ (MW=613.81): C, 66.53; H, 8.37; N, 6.85. Found: C, 66.22; H, 8.44; N, 6.91.

Diastereomer DF (1.28 g) [α]_(D) +16.5°, +68.4° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.33δ (CD₂ Cl₂).

Analysis Calcd. for C₃₄ H₅₁ N₃ O₇ (MW=613.81): C, 66.53; H, 8.37; N, 6.85. Found: C, 66.56; H, 8.36; N, 6.63.

EXAMPLE 11 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyltyrosyl-N-(tricyclo[3.3.1.13,7]dec-2-yl)-D-alaninamide UF isomer ##STR20## (Boc-2,6Me₂ Tyr-(D)Ala-NH2Ad)

The title compound was prepared by the method of Example 4 using the UF diastereomer of Example 10 in place of the UF diastereomer of Example 3.

Optical rotation [α]_(D) +32.6°; +179.5° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.04δ (CD₂ Cl₂).

Analysis Calcd. for C₂₉ H₄₃ N₃ O₅ ·1/2H₂ O (MW=523.70): C, 66.63; H, 8.48; N, 8.04. Found: C, 66.63; H, 8.29; N, 7.85.

EXAMPLE 12 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyltyrosyl-N-(tricyclo[3.3.1.13,7]dec-2-yl)-D-alaninamide DF isomer ##STR21## (Boc-2,6Me₂ Tyr-(D)Ala-NH2Ad)

The title compound was prepared by the method of Example 4 using the DF diastereomer of Example 10 in place of the UF diastereomer of Example 3.

Optical rotation [α]_(D) +23.3°; +83.6° (365) CHCl₃

NMR shift of the (D)Ala methyl=1.32δ (CD₂ Cl₂).

Analysis Calcd. for C₂₉ H₄₃ N₃ O₅ ·H₂ O (MW=531.71): C, 65.50; H, 8.53; N, 7.90. Found: C, 65.58; H, 8.13; N, 7.80.

EXAMPLE 13 2,6-dimethyltyrosyl-N-(tricyclo[3.3.1.13,7]dec-2-yl)-D-alaninamide, monohydrochloride UF isomer ##STR22## (2,6Me₂ Tyr-(D)Ala-NH2Ad·HCl)

The title material of Example 11 was deblocked by the method of Example 6.

Optical rotation [α]_(D) +111.2°; +418.5° (365) MeOH

NMR shift of the (D)Ala methyl=1.03δ (CD₃ OD).

Analysis Calcd. for C₂₄ H₃₆ N₃ O₃ Cl·1/2H₂ O (MW=459.04): C, 62.80; H, 8.12; N, 9.15. Found: C, 62.99; H, 8.00; N, 8.94.

EXAMPLE 14 2,6-dimethyltyrosyl-N-(tricyclo[3.3.1.13,7]dec-2-yl)-D-alaninamide, monohydrochloride DF isomer ##STR23##

The title material of Example 12 was converted to the title HCl salt by the method of Example 6.

Optical rotation [α]_(D) -55.5°; -233.6° (365) MeOH.

NMR shift of the (D)Ala methyl=1.28δ (CD₃ OD).

Analysis Calcd. for C₂₄ H₃₆ N₃ O₃ Cl·1/4H₂ O (MW=454.53): C, 63.42; H, 8.09; N, 9.25. Found: C, 63.48; H, 8.12; N, 9.12.

Route B

EXAMPLE 15 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-D-alanine, methyl ester ##STR24## (Boc-(DL)2,6Me₂ Tyr-(D)Ala-OMe)

Racemic t-butoxycarbonyl 2,6-dimethyltyrosine (3.9 g, 10 mmol) was dissolved in 30 ml of CH₂ Cl₂ by adding 1.12 ml (10 mmol) of NMM. After bringing this mixture to reflux it was cooled to -30° C. and 1.32 ml (10 mmol) of IBCF were added to this stirred solution. The temperature was allowed to rise to -15° C. and then lowered to -50° C. (D)alanine methyl ester hydrochloride (1.54 g, 11 mmol) was added to the solution followed by 1.3 ml (11 mmol) of NMM. The mixture was allowed to warm to room temperature and stand for 16 h. The majority of the CH₂ Cl₂ was removed under reduced pressure. Ethyl acetate (EtOAc, 200 ml) was added and this solution was washed twice with 100 ml portions of 0.5 molar KHSO₄, once with 100 ml of H₂ O and dried over MgSO₄. Removal of all solvent gave 3.9 g of the mixture of diastereomers. Recrystallization of this material from Skelly B(hexanes)/CH₂ Cl₂ produced 1.6 g (4.2 mmol) of diastereomer F. Removal of the solvent from the filtrate gave 1.3 g (3.3 mmol) of diastereomer S contaminated by less than 10% of diastereomer DF. The mixture of diastereomers or either of the separated diastereomers were used in subsequent examples without further purficiation.

Diastereomer DF:

NMR shift of the (D)Ala methyl=1.33δ (CD₂ Cl₂).

Diastereomer UF:

NMR shift of the (D)Ala methyl=1.16δ (CD₂ Cl₂).

EXAMPLE 16 N-[(1,1dimethylethoxy)carbonyl]-2,6-dimethyl-tyrosyl-D-alanine (UF isomer) ##STR25## (Boc-2,6Me₂ Tyr-(D)Ala)

A 13.0 g (33 mmol) sample of the title compound of Example 15 or its UF diastereomer was dissolved in 50 ml of MeOH. To this was added 50 ml of 1N NaOH. The mixture was stirred for 16 hours, acidified with 0.5N KHSO₄ to pH 2 and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO₄, and concentrated to produce 12 g (95%) of the product as a foam.

Diastereomer UF [α]_(D) +16.5° (CHCl₃).

NMR shift of the (D)Ala methyl=1.26δ (CD₂ Cl₂).

Analysis Calcd. for C₁₉ H₂₈ N₂ O₆ (MW=380.44): C, 59.99; H, 7.42; N, 7.36. Found: C, 59.19; H, 7.44; N, 7.17.

EXAMPLE 17 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-tyrosyl-D-alanine (DF isomer) ##STR26## (Boc-2,6Me₂ Tyr-(D)Ala)

The title compound was prepared by the methods of Example 16 using diastereomer DF of the title compound of Example 15.

Diastereomer DF [α]_(D) -21.7° (CHCl₃).

NMR shift of the (D)Ala methyl=1.26δ (CD₂ Cl₂).

EXAMPLE 18 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-(2,3-dihydro-1H-inden-1-yl)-D-alaninamide ##STR27## (Boc-2,6Me₂ Tyr-(D)Ala-NH-1Indane)

The title material from Example 16 (1.5 g, 3.9 mmol) was dissolved in 20 ml of CH₂ Cl₂. To this solution, gently stirred under an Ar atmosphere and cooled to -20° C., was added 0.40 g (3.9 mmol) of NMM followed by 0.54 g (3.9 mmol) of IBCF. After allowing the temperature of this mixture to come to 0° C., it was recooled to -10° and 0.53 g (3.9 mmol) of 1-amino indane were added. The reaction was warmed to room temperature and worked up as described in Example 1. The crude product was chromatographed (PLC) on silica gel eluting with 2%-5% MeOH/CHCl₃ to obtain the white solid title compound (1.3 g) as a mixture of diastereomers.

Analysis Calcd. for C₂₈ H₃₇ N₃ O₆ (MW=511.62): C, 65.73; H, 7.24; N, 8.21. Found: C, 65.36; H, 7.19; N, 8.01.

EXAMPLE 19 2,6-dimethyl-DL-tyrosyl-N-(2,3-dihydro-1H-inden-1-yl)-D-alaninamide, monohydrochloride ##STR28## ((DL)2,6Me₂ Tyr-(D)Ala-NH-1-Indane·HCl)

The title compound of Example 18 was deblocked and converted to its HCl salt by the method of Example 6.

Analysis Calcd. for C₂₃ H₃₀ N₃ O₃ Cl·1/2H₂ O (MW=440.97): Calc.: C, 62.64; H, 7.10; N, 9.53; Cl, 8.04. Found: C, 62.61; H, 7.09; N, 9.09; Cl, 7.70.

ROUTE A

EXAMPLE 20 phenylmethyl [2-[(2,3-dihydro-1H-inden-2-yl)amino]-1R-methyl-2-oxoethyl]carbamate ##STR29## (Z-(D)Ala-NH-2Indane)

The title compound was prepared from Z-(D)Alanine (10 g, 44.8 mmol) and 2-amino indane hydrochloride (7.6 g, 44.8 mmol) by the method of Example 8. After workup, the crude solid was washed liberally with Et₂ O to give 12.35 g of the white solid title material.

Optical rotation [α]_(D) +3.0°; +0.5° (365) CHCl₃.

NMR shift of (D)Ala methyl=1.28δ (CD₂ Cl₂).

Analysis Calcd. for C₂₀ H₂₂ N₂ O₅ (MW=338.41): C, 70.99; H, 6.55; N, 8.28. Found: C, 71.10; H, 6.50; N, 8.27.

EXAMPLE 21

2R-amino-N-(2,3-dihydro-1H-inden-2-yl)propanamide ##STR30##

((D)Ala-NH-2Indane)

The title material was prepared from the title material of Example 20 by the method of Example 9.

Optical rotation [α]_(D) +21.6°; +68.6° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.23δ (CD₂ Cl₂).

Analysis Calcd. for C₁₂ H₁₆ N₂ O (MW=204.16): C, 70.56; H, 7.89; N, 13.71. Found: C, 70.40; H, 7.94; N, 13.67.

EXAMPLE 22 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-O-[(2-methylpropoxy)carbonyl]-DL-tyrosyl-N-(2,3-dihydro-1H-inden-2-yl)-D-alaninamide ##STR31## (Boc-(DL)2,6Me₂ Tyr(IBC)-(D)Ala-NH-2Indane)

The title mixture of diastereomers was prepared as described in Example 3 using the title material of Example 21 in place of that from Example 2. Only the DF-diastereomer was isolated pure by PLC on Woelm® silica eluting with 2% EtOH/CHCl₃.

Diastereomer S [α]_(D) +6.6°; +13.3° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.29δ (CD₂ Cl₂).

Analysis Calcd for C₃₃ H₄₄ N₃ O₇ (MW=594.74): C, 66.64; H, 7.46; N, 7.07. Found: C, 66.48; H, 7.43; N, 6.93.

EXAMPLE 23 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyltyrosyl-N-(2,3-dihydro-1H-inden-2-yl)-D-alaninamide DF isomer ##STR32## (Boc-2,6Me₂ Tyr-(D)Ala-NH-2Indane)

The title compound was prepared by the method of Example 4 using the title compound of Example 22 in place of the UF diastereomer of Example 3.

Optical rotation [α]_(D) +7.5°; +40.4° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.28δ (CD₂ Cl₂).

Analysis Calcd. for C₂₈ H₃₇ N₃ O₅ (MW=495.62): C, 67.85; H, 7.52; N, 8.48. Found: C, 67.56; H, 7.49; N, 8.19.

EXAMPLE 24 2,6-dimethyltyrosyl-N-(2,3-dihydro-1H-inden-2-yl)-D-alaninamide, monohydrochloride DF isomer ##STR33## (2,6Me₂ Tyr-(D)Ala-NH-2Indane·HCl)

The title material was prepared by deblocking the title compound of Example 23 using the methods of Example 6.

Optical rotation [α]_(D) -82.6°; -300.0° (365) MeOH.

NMR shift of the (D)Ala methyl=1.27δ (CD₃ OD).

Analysis Calcd. for C₂₃ H₃₀ N₃ O₃ Cl·3/4H₂ O (MW=445.48): C, 62.01; H, 7.13; N, 9.43; Cl, 7.87. Found: C, 62.05; H, 6.91; N, 9.28; Cl, 8.21.

EXAMPLE 25 phenylmethyl [1R-methyl-2-oxo-2-(1,2,3,4-tetrahydro-1-quinolinyl)ethyl]carbamate ##STR34## (Z-(D)Ala-THQuinoline)

The title compound was prepared from Z-(D)Alanine and 1,2,3,4-tetrahydroquinoline by the method of Example 8. After workup, the crude pale yellow oil product was used in subsequent reactions without further purification. NMR shift of the (D)Ala methyl=1.16δ (CD₂ Cl₂).

EXAMPLE 26 1-(2R-amino-1-oxopropyl)-1,2,3,4-tetrahydro-quinoline, monohydrochloride ##STR35## ((D)Ala-THQuinoline·HCl)

The free base of the title material was prepared from the title material of Example 25 (11.4 g, 34.0 mmol) by the method of Example 9. This material was then dissolved in 300 ml of Et₂ O and treated with 12 ml of 6.2N HCl/dioxane. The precepitated white solid title salt was suction filtered, washed with Et₂ O, and vacuum dried (7.47 g).

Optical rotation [α]_(D) -87.7°; -519.6° (365) MeOH.

NMR shift of the (D)Ala methyl=1.30δ (CD₃ OD).

Analysis Calcd. for C₁₂ H₁₇ N₂ OCl (MW=240.73): C, 59.87; H, 7.12; N, 11.64. Found: C, 59.84; H, 7.13; N, 11.60.

EXAMPLE 27 4-[2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-[[1R-methyl-2-oxo-2-(1,2,3,4-tetrahydro-1-quinolinyl)ethyl]amino]-3-oxopropyl]-3,5-dimethylphenyl 2-methylpropane carbonate ##STR36## (Boc-(DL)2,6Me₂ Tyr(IBC)-(D)Ala-THQuinoline)

The title mixture of diastereomers was prepared as described in Example 3 using the title material of Example 26 in place of Example 2 material. The unseparated diastereomers were isolated by LPC and used without further purification.

EXAMPLE 28 α-[[(1,1-dimethylethoxy)carbonyl]amino]-4-hydroxy-2,6-dimethyl-N-[1R-methyl-2-oxo-2-(1,2,3,4-tetrahydro-1-quinolinyl)ethyl]benzenepropanamide ##STR37## (Boc-(DL)2,6Me₂ Tyr-(D)Ala-THQuinoline)

The title mixture of diastereomers was prepared by the method of Example 4 using the title mixture of Example 27 in place of the F diastereomer of Example 3. Both diastereomers were separated on a Waters Prep 500 with a C₁₈ reverse phase cartridge eluting with 30% acetonitrile/water.

Diastereomer DF: [α] -67.3°; -354.0° (365) CHCl₃.

Analysis Calcd. for C₂₈ H₃₇ N₃ O₅ ·1/2H₂ O (MW=504.64): C, 66.64; H, 7.59; N, 8.33. Found: C, 66.40; H, 7.41; N, 7.94.

Diastereomer UF [α]_(D) -44.8°: -242.4° (365) MeOH.

Analysis Calcd. for C₂₈ H₃₇ N₃ O₅ ·1/4H₂ O (MW=500.14): C, 67.24; H, 7.56; N, 8.40. Found: C, 67.52; H, 7.55; N, 7.95.

EXAMPLE 29 αS-R*-amino-4-hydroxy-2,6-dimethyl-N-[1S*-methyl-2-oxo-2-(1,2,3,4-tetrahydro-1-quinolinyl)ethyl]benzenepropanamide, monohydrochloride DF isomer ##STR38## (2,6Me₂ Tyr-(D)Ala-THQuinoline·HCl)

The title material was prepared from the F diastereomer (rev. phase) of Example 28 by the method of Example 6.

Optical rotation [α]_(D) -97.4°; -418.8° (365) MeOH.

NMR Shift of the (D)Ala methyl=1.20δ (CD₃ OD).

Analysis Calcd. for C₂₃ H₃₀ N₃ O₃ Cl·3/4H₂ O (MW=445.48): C, 62.01; H, 7.12; N, 9.43. Found: C, 62.08; H, 7.33; N, 8.51.

EXAMPLE 30 α-amino-4-hydroxy-2,6-dimethyl-N-[1R-methyl-2-oxo-2-(1,2,3,4-tetrahydro-1-quinolinyl)ethyl]benzenepropanamide, monohydrochloride UF isomer ##STR39## (2,6-Me₂ Tyr-(D)Ala-THQuinoline·HCl)

The title compound was prepared from the S diastereomer (rev phase) of Example 28 using the methods of Example 6.

Optical rotation [α]_(D) +24.7°; +36.6° (365) MeOH.

NMR shift of the (D)Ala methyl=0.91δ (CD₃ OD).

Analysis Calcd. for C₂₃ H₃₀ N₃ O₃ Cl·11/2H₂ O (MW=458.99): C, 60.19; H, 7.25; N, 9.16. Found: C, 60.46; H, 7.18; N, 8.72.

EXAMPLE 31 phenylmethyl [1R-methyl-2-oxo-2-(1,2,3,4-tetrahydro-2-isoquinolinyl)ethyl]carbamate ##STR40## (Z-(D)Ala-THIsoquinoline)

The title material was synthesized from Z-(D)Alanine and 1,2,3,4-tetrahydroisoquinoline by the method of Example 8. Following workup, the crude product oil was purified by chromotagraphy on a Waters Prep 500 using a Porasil cartridge and eluting with 3-5% EtOAc/CH₂ Cl₂.

Optical rotation [α]_(D) -4.3°; -20.9° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.33δ (CD₂ Cl₂).

Analysis Calcd. for C₂₀ H₂₂ N₂ O₃ (MW=338.41): C, 70.98; H, 6.55; N, 8.28. Found: C, 70.55; H, 6.61; N, 8.21.

EXAMPLE 32 2-(2R-amino-1-oxopropyl)-1,2,3,4-tetrahydroisoquinoline, monohydrochloride ##STR41## ((D)Ala-THIsoquinoline·HCl)

The title compound was prepared by the method of Example 26 using the title material of Example 31 in place of that from Example 25.

Optical rotation [α]_(D) +30.3°; +88.1° (365) MeOH.

NMR shift of the (D)Ala=1.50δ (CD₃ OD).

Analysis Calcd. for C₁₂ H₁₇ N₂ OCl·1/4H₂ O (MW=245.24): C, 58.77; H, 7.19; N, 11.42. Found: C, 59.06; H, 6.99; N, 11.59.

EXAMPLE 33 4-[2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-[[1R-methyl-2-oxo-2-(1,2,3,4-tetrahydro-2-isoquinolinyl)ethyl]amino-3-oxopropyl]-3,5-dimethylphenyl 2-methylpropane carbonate ##STR42## (Boc-(DL)2,6Me₂ Tyr(IBC)-(D)Ala-THIsoquinoline)

The title mixture of diastereomers was synthesized as described in Example 3 using the title material of Example 32 in place of that from Example 2. Both diastereomers were separated by PLC on Merck® silica eluting with 5-7% EtOAc/CH₂ Cl₂.

Diastereomer UF [α]_(D) +10.0°; +31.8° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.04δ (CD₂ Cl₂).

Analysis Calcd. for C₃₃ H₄₅ N₃ O₇ (MW=595.74): C, 66.53; H, 7.61; N, 7.05. Found: C, 66.87; H, 7.58; N, 6.73.

Diastereomer DF [α]_(D) -15.3°; -58.7° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.28δ (CD₂ Cl₂).

Analysis Calcd. for C₃₃ H₄₅ N₃ O₇ (MW=595.74): C, 66.53; H, 7.61; N, 7.05. Found: C, 66.82; H, 7.58; N, 6.76.

EXAMPLE 34 1,1-dimethylethyl [1-[(4-hydroxy-2,5-dimethylphenyl)methyl]-2-[[1R-methyl-2-oxo-2-(1,2,3,4-tetrahydro-2-isoquinolinyl)ethyl]amino]-2-oxoethyl]carbamate, isomer UF ##STR43## Boc-2,6Me₂ Tyr-(D)Ala-THIsoquinoline)

The title compound was prepared by the method of Example 4 using the F diastereomer of Example 33 in place of the UF diastereomer of Example 3.

Optical rotation [α] +18.8°; +87.9° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.07δ (CD₂ Cl₂).

Analysis Calcd. for C₂₈ H₃₇ N₃ O₅ (MW=495.63): C, 67.85; H, 7.52; N, 8.48. Found: C, 67.56; H, 7.31; N, 8.44.

EXAMPLE 35 α-amino-4-hydroxy-2,6-dimethyl-N-[1R-methyl-2-oxo-2-(1,2,3,4-tetrahydro-2-isoquinolinyl)ethyl]benzenepropanamide, monohydrochloride, isomer S UF isomer ##STR44## (2,6Me₂ Tyr-(D)Ala-THIsoquinoline·HCl)

The title compound was synthesized from the title material of Example 34 by the method of Example 6.

Optical rotation [α]_(D) +125.2°; +467.0° (365) CH₃ OH.

NMR shift of the (D)Ala methyl=1.08δ (CD₃ OD).

Analysis Calcd. for C₂₃ H₃₀ N₃ O₃ Cl·1/2H₂ O (MW=440.98): C, 62.64; H, 7.09; N, 9.53; Cl, 8.04. Found: C, 62.66; H, 7.42; N, 8.85; Cl, 7.82.

EXAMPLE 36 1,1-dimethylethyl [1-[(4-hydroxy-2,5-dimethylphenyl)methyl]-2-[[1R-methyl-2-oxo-2-(1,2,3,4-tetrahydro-2-isoquinolinyl)ethyl]amino]-2-oxoethyl]carbamate, isomer DF ##STR45## (Boc-2,6Me₂ Tyr-(D)Ala-THIsoquinoline)

The title compound was prepared by the method of Example 4 using the S diastereomer of Example 33 in place of the F diastereomer of Example 3.

Optical rotation [α]_(D) -5.7°; -23.0° (365) CHCl₃.

NMR of the (D)Ala methyl=1.24δ (CD₂ Cl₂).

Analysis Calcd. for C₂₈ H₃₇ N₃ O₅ (MW=495.63): C, 67.85; H, 7.52; N, 8.48. Found: C, 67.79; H, 7.41; N, 8.40.

EXAMPLE 37 α-amino-4-hydroxy-2,6-dimethyl-N-[1R-methyl-2-oxo-2-(1,2,3,4-tetrahydro-2-isoquinolinyl)ethyl]benzenepropanamide, monohydrochloride DF isomer ##STR46## (2,6Me₂ Tyr-(D)Ala-THIsoquinoline·HCl)

The title compound was synthesized from the title material of Example 36 by the method of Example 6.

Optical rotation [α]_(D) -72.7°; -281.8° (365) MeOH.

NMR shift of the (D)Ala methyl=1.28δ (CD₃ OD).

Analysis Calcd. for C₂₃ H₃₀ N₃ O₃ Cl·1/2H₂ O (MW=440.98): C, 62.64; H, 7.09; N, 9.53; Cl, 8.04. Found: C, 62.73; H, 7.09; N, 9.24; Cl, 8.13.

ROUTE B

EXAMPLE 38 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-L-tyrosyl-N-[2-(2-thienyl)ethyl]-D-alaninamide UF isomer ##STR47## (Boc-2,6Me₂ Tyr-(D)Ala-NH(CH₂)₂ -2-thiophene)

The title compound was prepared by the method of Example 18 using 2-thienylethylamine in place of 1-aminoindane and purified by PLC on Merck® silica eluting with 1-2% EtOH/CHCl₃.

Optical rotation [α]_(D) +38.3°; +157.4° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.04δ (CDCl₃).

Analysis Calcd. for C₂₅ H₃₅ N₃ O₅ S (489.65): C, 61.33; H, 7.20; N, 8.58; S, 6.55. Found: C, 60.97; H, 7.10; N, 8.46; S, 6.38.

EXAMPLE 39 2,6-dimethyl-L-tyrosyl-N-[2-(2-thienyl)ethyl]-D-alaninamide, monohydrochloride UF isomer ##STR48## (2,6-Me₂ Tyr-(D)Ala-NH(CH₂)₂ -thiophene·HCl)

The title compound of Example 38 was deblocked and converted to its HCl salt, the title material, by the method of Example 6.

Optical rotation [α]_(D) +101.0°; +364.0° (365) MeOH.

NMR shift of the (D)Ala methyl=0.99δ (CD₃ OD).

Analysis Calcd. for C₂₀ H₂₈ N₃ O₃ SCl (MW=425.99): C, 55.22; H, 6.72; N, 9.66. Found: C, 55.50; H, 7.15; N, 9.45.

ROUTE A

EXAMPLE 40 2-thiopheneethanol, 4-methylbenzenesulfonate ##STR49##

2-thienylethonol (15.0 g, 0.12 mol) dissolved in 75 ml of pyridine was cooled to 0° C. before 22.3 g (0.12 mol) of p-toluenesulfonylchloride were added to the stirred solution under N₂. After stirring this reaction for 2 h at 0° C., it was poured onto ice (˜200 g) and this mixture was stirred until all the ice had melted. This two phase mixture was extracted 3×200 ml of Et₂ O and these ether extracts were washed 2×125 ml of H₂ O, 3×125 ml of 0.5N KHSO₄ and 1×200 ml of H₂ O, dried over Na₂ SO₄, and stripped of all solvent under reduced pressure. The resulting pale red liquid product (33.0 g) was used without further purification.

EXAMPLE 41 2-thiophenepropanenitrile ##STR50##

The product of Example 40 (31.1 g, 0.11 mol) was dissolved in a mixture of 540 ml of acetone and 60 ml of water. To this solution was added 19.0 g (0.3 mol) of potossium cyanide. After refluxing this mixture for 48 h under N₂, it was cooled to room temperature and all solvent was removed under reduced pressure. The residue was diluted with 600 ml of H₂ O and extracted 3×200 ml of Et₂ O. The combined Et₂ O extracts were washed with 150 ml of 0.5N KHSO₄ and 150 ml of brine before drying over Na₂ SO₄. After the solvent was removed under reduced pressure the crude product was purified on a

Waters Prep 500 chromotograph with a Porasil cartridge eluting with 100% toluene (yield=11.8 g).

Analysis Calcd. for C₇ H₇ NS (MW=137.20): C, 61.28; H, 5.14; N, 10.20; S, 23.37. Found: C, 61.60; H, 5.08; N, 10.03; S, 22.13.

EXAMPLE 42 2-thiophenepropanamine ##STR51##

The product of Example 41 (8.3 g, 10.5 mmol) dissolved in 25 ml of Et₂ O was added dropwise (15 min.) to a stirred slurry of lithium aluminium hydride (LAH) in 125 ml of dry Et₂ O under an Ar atmosphere at room temperature. After the addition was complete the reaction was stirred at room temperature an additional 18 h. With great care, 8.0 ml of water were added dropwise to the vigorously stirred reaction mixture. Following this, 8.0 ml of 4N NaOH were then carefully added. Finally 22 ml of H₂ O were added and the aluminum salts were filtered from the Et₂ O solution. The filtrate was concentrated to give 8.24 g of the title products which was used without further purification.

EXAMPLE 43 1,1-dimethylethyl [1R-methyl-2-oxo-2-[[3-(2-thienyl)propyl]amino]ethyl]carbamate ##STR52## (Boc-(D)Ala-NH(CH₂)₃ -2-thiophene)

The title compound was prepared by the method of Example 1 using the title material of Example 42 in place of 6-aminohexanoic acid methyl ester hydrochloride and one equivalent less of NMM.

Optical rotation [α]_(D) +8.0°; +33.6° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.28δ (CD₂ Cl₂).

Analysis Calcd. for C₁₅ H₂₄ N₂ O₃ S·1/4H₂ O (MW=316.95): C, 56.84; H, 7.79; N, 8.84; S, 10.12. Found: C, 56.44; H, 7.54; N, 8.66; S, 9.76.

EXAMPLE 44 2R-amino-N-[3-(2-thienyl)propyl]propanamide ##STR53## ((D)Ala-NH(CH₂)₃ -2-thiophene)

The title material of Example 43 (7.9 g, 25.2 mmol) was deblocked by the method of Example 2 to produce the HCl salt. To this material was added 75 ml of 10% potassium bicarbonate (KHCO₃) and 100 ml of CH₂ Cl₂. The organic layer was separated, washed with brine (50 ml), dried over Na₂ SO₄, and stripped of all solvent to give 4.49 g of the title product as a pale yellow viscous liquid.

Optical rotation [α]_(D) -9.4°; +9.4° (365) CHCl₃.

NMR of the (D)Ala methyl=1.25δ (CD₂ Cl₂).

Analysis Calcd. for C₁₀ H₁₆ N₂ OS (MW=212.32): C, 56.57; H, 7.60; N, 13.19. Found: C, 56.33; H, 7.63; N, 12.92.

EXAMPLE 45 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-[3-(2-thienyl)propyl]-D-alaninamide ##STR54## (Boc-2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ -2-thiophene)

Racemic t-butoxycarbonyl-2,6-dimethyltyrosine (3.5 g, 11.3 mmol) in 40 ml of CH₂ Cl₂ was stirred with molecular sieve 5A under Ar for 30 min before being cooled to 0° C. NMM (1.24 ml, 11.3 mmol) was added to this mixture before it was cooled further to -78° C. IBCF (1.5 ml, 11.3 mmol) was then added and the mixture was allowed to warm to room temperature. After 30 min at room temperature, the reaction was cooled to -78° C. and charged with 2.4 g (11.3 mmol) of the title compound of Example 44. This mixture was allowed to warm to room temperature and stir an additional 18 h. The crude product mixture of diastereomers, obtained on workup as described in Example 1, was separated by PLC on Woelm® silica eluting with 1.5% MeOH/CHCl₃.

Diastereomer DF [α]_(D) +4.3°; +19.6° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.23δ (CD₂ Cl₂).

Analysis Calcd. for C₂₆ H₃₇ N₃ O₅ S (MW=503.67): C, 62.00; H, 7.40; N, 8.34; S, 6.37. Found: C, 62,42; H, 7.41; N, 8.07; S, 6.24.

Diastereomer UF [α]_(D) +41.0°; +166.7° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.04δ (CD₂ Cl₂).

Analysis Calcd. for C₂₆ H₃₇ N₃ O₅ S (MW=503.67): C, 62.00;1 H, 7.40; N, 8.34; S, 6.37. Found: C, 61.73; H, 7.25; N, 8.14; S, 6.19.

EXAMPLE 46 2,6-dimethyltyrosyl-N-[3-(2-thienyl)propyl]-D-alaninamide, monohydrochloride DF isomer ##STR55## (2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ -2-Thiophene·HCl)

The title product was obtained from the DF diastereomer of Example 45 by the method of Example 6.

Optical rotation [α]_(D) -60.5°; -236.3° (365) MeOH.

NMR shift of the (D)Ala methyl=1.28δ (CD₃ OD).

Analysis Calcd. for C₂₁ H₃₀ N₃ O₃ S Cl (MW=440.01): C, 57.33; H, 6.87; N, 9.55; S, 7.29; Cl 8.06. Found: C, 57.17; H, 6.76; N, 9.30; S, 7.28; Cl, 7.87.

EXAMPLE 47 2,6-dimethyltyrosyl-N-[3-(2-thienyl)propyl]-D-alaninamide, monohydrochloride UF isomer ##STR56## (2,6-Me₂ Tyr-(D)Ala-NH(CH₂)₃ -2-thiophene·HCl)

The title material was obtained from the UF diastereomer of Example 45 by the method of Example 6.

Optical rotation [α]_(D) +126.5°; +433.5° (365) MeOH.

NMR of the (D)Ala methyl=1.03δ (CD₃ OD).

Analysis Calcd. for C₂₁ H₃₀ N₃ O₃ SCl (MW=440.01): C, 57.33; H, 6.87; N, 9.55; S, 7.29; Cl, 8.06. Found: C, 57.04; H, 6.77; N, 9.29; S, 7.24; Cl, 7.90.

Corresponding 3-thiophene diastereomers were made using the similar procedures of examples 43, 44, 45 & 46 beginning with the 3-thiophenepropanamine.

2,6-dimethyltyrosyl-N-[3-(3-thienyl)propyl]-D-alaninamide, monohydrochloride DF isomer

Optical rotation [α]_(D) -59.6°; -223.0° (365) MeOH.

NMR shift of the (D)Ala methyl=1.27δ (CD₃ OD).

Analysis Calcd. for C₂₁ H₃₀ N₃ O₃ SCl (MW=440.01) C, 57.33; H, 6.87; N, 9.55; S, 7.29; Cl, 8.06 Found: C, 57.29; H, 7.08; N, 9.78; S, 7.47; Cl, 7.82

2,6-dimethyltyrosyl-N-[3-(3-thienyl)propyl]-D-alaninamide, monohydrochloride UF isomer

Optical rotation [α]_(D) +27.5°; +393.3° (365) MeOH.

NMR of the (D)Ala methyl=1.04δ (CD₃ OD).

Analysis Calcd. for C₂₁ H₃₀ N₃ O₃ SCl (MW=440.01) C, 57.33; H, 6.87; N, 9.55; S, 7.29; Cl, 8.06. Found: C, 56.98; H, 7.00; N, 9.62; S, 7.41; Cl, 7.26.

EXAMPLE 48 ##STR57##

To a solution of 2-(3-(2-thienyl)-2E-propenyl]-1H-isoindole-1,3(2H)-dione (9.8 g, 36.4 mmol) dissolved in 300 ml EtOH was added 7.1 ml (145.5 mmol) of hydrazine hydrate (NH₂ NH₂ ·H₂ O). The stirred mixture under N₂ was refluxed for 2 hours before cooling to room temperature and standing overnight. The precipitated 2,3-dihydro-1,4-phthalazinedione biproduct was filtered off and the filtrate concentrated precipitating additional solid. After again filtering off the solid biproduct the filtrate was concentrated, filtered, dried over Na₂ SO₄ and stripped of all solvent under reduced pressure to give 4.48 g of the title product. This material was used in subsequent reactions without further purification.

EXAMPLE 49 1,1-dimethylethyl [1R-methyl-2-oxo-2-[[3-(2-thienyl)-2E-propenyl]amino]ethyl]carbamate ##STR58## (Boc-(D)Ala-NHCH₂ (CH)₂ -2-thiophene)

The title compound was prepared by the method of Example 1 using the title material from Example 48 in place of 6-aminohexanoic acid methylester hydrochloride and one equivalent less of NMM.

Optical rotation [α]_(D) +18.6°; +43.7° (365) CHCl₂.

NMR shift of the (D)Ala methyl=1.33δ (CD₂ Cl₂).

Analysis Calcd. for C₁₅ H₂₂ N₂ O₃ S (MW=310.42): C, 58.04; H, 7.14; N, 9.02; S, 10.33. Found: C, 57.96; H, 7.18; N, 9.02; S, 10.70.

EXAMPLE 50 2R-amino-N-[3-(2-thienyl)-2E-propenyl]propanamide, monohydrochloride ##STR59## ((D)Ala-NHCH₂ (CH)₂ -2thiophene·HCl)

The title compound was prepared by the method of Example 2 from the title material of Example 49.

Optical rotation [α]_(D) -7.8° (MeOH).

NMR shift of the (D)Ala methyl=1.48δ (CD₃ OD).

Analysis Calcd. for C₁₀ H₁₅ N₂ SO Cl·1/4H₂ O (MW=251.27): C, 47.80; H, 6.22; N, 11.15; Cl, 14.10; S, 12.76. Found: C, 48.08; H, 5.97; N, 10.85; Cl, 13.68; S, 12.47.

EXAMPLE 51 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-[3-(2-thienyl)-2E-propenyl]-D-alaninamide ##STR60## (Boc-(DL)2,6Me₂ Tyr-(D)Ala-NHCH₂ (CH)₂ -2-thiophene)

The title mixture of diastereomers were prepared and separated by the method of Example 45 using the title material from Example 50 in place of the title amide of Example 44.

Diastereomer DF [α] -17.3°; -33.5° (365) CHCl₃.

NMR of the (D)Ala methyl=1.31δ (CD₂ Cl₂).

Analysis Calcd. for C₂₆ H₃₅ N₃ O₅ S·1/4H₂ (MW=506.15): C, 61.47; H, 6.99; N, 7.94; S, 6.86. Found: C, 61.59; H, 7.08; N, 7.99; S, 6.38.

Diastereomer UF [α]_(D) +11.1°; +73.4° (365) CHCl₃.

NMR of the (D)Ala methyl=1.03δ (CD₂ Cl₂).

Analysis Calcd. for C₂₆ H₃₅ N₃ O₅ S·1/4H₂ O (MW=506.15): C, 61.47; H, 6.99; N, 7.94; S, 6.86. Found: C, 61.69; H, 7.07; N, 8.30; S, 6.32.

EXAMPLE 52 2,6-dimethyltyrosyl-N-[3-(2-thienyl)-2E-propenyl]-D-alaninamide, monohydrochloride UF isomer ##STR61## (2,6Me₂ Tyr-(D)Ala-NHCH₂ (CH)₂ -2-thiophene·HCl)

The title compound was synthesized from the UF diastereomer of Example 51 by the method of Example 6.

Optical rotation [α]_(D) +62.3°; +226.0° (365) CH₃ OH.

NMR shift of the (D)Ala methyl=1.40δ (CD₃ OD).

Analysis Calcd. for C₂₁ H₂₈ N₃ O₃ SCl·2H₂ O (MW=474.02): C, 53.21; H, 6.80; N, 8.86; S, 6.76; Cl, 7.48. Found: C, 52.92; H, 6.06; N, 8.29; S, 6.42; Cl, 7.50.

EXAMPLE 53 ##STR62##

The title compound was prepared from its phthalamide precursor, 2-[3-(3-thienyl)-=2E-propenyl]-1H-isoindole-1,3(2H)-dione by the method of Example 48. The crude reaction product was used in subsequent reactions without further purification.

EXAMPLE 54 1,1-dimethylethyl [1R-methyl-2-oxo-2-[[3-(3-thienyl)-2E-propenyl]amino]ethyl]carbamate ##STR63## (Boc-(D)Ala-NHCH₂ (CH)₂ -3-thiophene)

The title material was prepared by the method of Example 1 using the title compound from Example 53 in place of

6-aminohexanoic acid methylester hydrochloride and one equivalent less of NMM.

Optical rotation [α]_(D) =+10.7°; +35.6° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.32δ (CD₂ Cl₂).

Analysis Calcd. for C₁₅ H₂₂ N₂ O₃ S (MW=310.42): C, 58.04; H, 7.14; N, 9.02; S, 10.33. Found: C, 57.98; H, 7.16; N, 8.97; S, 10.73.

EXAMPLE 55 2R-amino-N-[3-(3-thienyl)-2E-propenyl]propanamide, monohydrochloride ##STR64## ((D)Ala-NHCH₂ (CH)₂ -3thiophene·HCl)

The title material was prepared by the method of Example 2 from the title compound of Example 54.

Optical rotation [α]_(D) -13.7° MeOH.

NMR shift of the (D)Ala methyl=1.52δ (CD₃ OD).

Analysis Calcd. for C₁₀ H₁₅ N₂ OSCl·1/4H₂ O (251.27): C, 47.80; H, 6.22; N, 11.15; S, 12.76; Cl, 14.10. Found: C, 48.16; H, 5.90; N, 11.17; S, 12.65; Cl, 13.72.

EXAMPLE 56 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-[3-(3-thienyl)-2E-propenyl]-D-alaninamide ##STR65## (Boc-(DL)2,6Me₂ Tyr-(D)Ala-NHCH₂ (CH)₂ -3thiophene)

The title mixture of diastereomers were prepared and separated by the method of Example 45 using the title material from Example 55 in place of the title amide of Example 44.

Diastereomer DF [α]_(D) -9.2°; -39.2° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.32δ (CD₂ Cl₂).

Analysis Calcd. for C₂₆ H₃₅ N₃ O₅ S·1/4H₂ O (MW=506.15): C, 61.70; H, 7.07; N, 8.30; S, 6.33. Found: C, 61.71; H, 6.96; N, 8.11; S, 6.35.

Diastereomer UF [α]_(D) +26.3°; +129.8° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.07δ (CD₂ Cl₂).

Analysis Calcd. for C₂₆ H₃₅ N₃ O₅ S (MW=501.66): C, 62.25; H, 7.03; N, 8.39; S, 6.39. Found: C, 62.35; H, 7.09; N, 7.97; S, 6.39.

EXAMPLE 57 2,6-dimethyltyrosyl-N-[3-(3-thienyl)-2E-propenyl]-D-alaninamide, monohydrochloride DF isomer ##STR66## ((D)2,6Me₂ Tyr-(D)Ala-NHCH₂ (CH)₂ -3-thiophene·HCl)

The title compound was synthesized from the DF diastereomer of Example 56 by the method of Example 6.

Optical rotation [α]_(D) -75.1°; -283.9° (365) CH₃ OH.

NMR shift of the (D)Ala methyl=1.30δ (CD₃ OD).

Analysis Calcd. for C₂₁ H₂₈ N₃ O₃ SCl·H₂ O (456.01): C, 55.31; H, 6.63; N, 9.21; S, 7.03; Cl, 7.77. Found: C, 55.06; H, 6.34; N, 8.83; S, 6.67; Cl, 8.18.

EXAMPLE 58 2,6-dimethyltyrosyl-N-[3-(3-thienyl)-2E-propenyl]-D-alaninamide, monohydrochloride UF isomer ##STR67## (2,6Me₂ Tyr-(D)Ala-NHCH₂ (CH)₂ -3-thiophene·HCl)

The title compound was prepared from the UF diastereomer of Example 57 by the method of Example 6.

Optical rotation [α]_(D) +86.8°; +335.6° (365) MeOH.

NMR shift of the (D)Ala methyl=1.06δ (CD₃ OD).

Analysis Calcd. for C₂₁ H₂₈ N₃ O₃ SCl·1/2H₂ O (437.00): C, 56.42; H, 6.54; N, 9.40; S, 7.17; Cl, 7.93. Found: C, 56.65; H, 6.54; N, 9.09; S, 6.93; Cl, 7.88.

EXAMPLE 59 phenylmethyl [2-[[3-(4-methoxyphenyl)propyl]amino]-1R-methyl-2-oxoethyl]carbamate ##STR68## (Z-(D)Ala-NH(CH₂)₃ -Ph(4-OMe))

The title compound was prepared by the method of Example 8 using NH₂ (CH₂)₃ Ph(4-MeO) in place of NH2Ad·HCl and one equivalent less of NMM.

Optical rotation [α]_(D) +21.8°; +83.7° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.31δ (CD₂ Cl₂).

Analysis Calcd. for C₂₁ H₂₆ N₂ O₄ (MW=370.46): C, 68.09; H, 7.07; N, 7.56. Found: C, 68.02; H, 6.90; N, 7.45.

EXAMPLE 60 αR-amino-N-[3-(4-methoxyphenyl)propyl]propanamide ##STR69## ((D)Ala-NH(CH₂)₃ Ph(4-OMe))

The title compound was prepared from the title material of Example 59 by the method of Example 9.

Optical rotation [α]_(D) -11.2°; +5.6° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.27δ (CD₂ Cl₂).

Analysis Calcd. for C₁₃ H₂₀ N₂ O₂ ·1/4H₂ O (MW=240.83): C, 64.84; H, 8.58; N, 11.63. Found: C, 64.81; H, 8.62; N, 10.91.

EXAMPLE 61 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-[3-(4-methoxyphenyl)propyl]-D-alaninamide ##STR70## (Boc-(DL)2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ Ph(4-OMe))

The title mixture of diastereomers was prepared and separated by the method of Example 45 using the title material from Example 59 in place of the title amide of Example 44.

Diastereomer DF [α]_(D) +9.1°; +18.3° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.30δ (CD₂ Cl₂).

Analysis Calcd. for C₂₉ H₄₁ N₃ O₆ (MW=527.67): C, 66.01; H, 7.83; N, 7.96. Found: C, 66.08; H, 7.75; N, 7.95.

Diastereomer UF [α]_(D) +41.7°; +176.7° (365) CHCl₃.

NMR shift of the (D)Ala methyl=1.05δ (CD₂ Cl₂).

Analysis Calcd. for C₂₉ H₄₁ N₃ O₆ (MW=527.67): C, 66.01; H, 7.83; N, 7.96. Found: C, 65.64; H, 7.80; N, 7.75.

EXAMPLE 62 2,6-dimethyltyrosyl-N-[3-(4-methoxyphenyl)propyl]-D-alaninamide, monohydrochloride DF isomer ##STR71## ((D)2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ Ph(4-OMe)·HCl)

The title compound was synthesized from the DF diastereomer of Example 61 by the method of Example 6.

Optical rotation [α]_(D) -67.3°; -230.9° (365) MeOH.

NMR shift of the (D)Ala methyl=1.27δ (CD₃ OD).

Analysis Calcd. for C₂₄ H₃₄ N₃ O₄ Cl·1/4H₂ O (MW=464.02): C, 61.52; H, 7.42; N, 8.97; Cl, 7.57. Found: C, 61.62; H, 7.23; N, 8.92; Cl, 7.10.

EXAMPLE 63 2,6-dimethyltyrosyl-N-[3-(4-methoxyphenyl)propyl]-D-alaninamide, hydrochloride UF isomer ##STR72## (2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ Ph(4-OMe)·HCl)

The title material was prepared from the UF diastereomer of Example 61 by the method of Example 6.

Optical rotation [α]_(D) +99.0°; +362.0° (365) MeOH.

NMR shift of the (D)Ala methyl=1.04δ (CD₃ OD).

Analysis Calcd. for C₂₄ H₃₃ N₃ O₄ ·11/8HCl·3/4H₂ O (MW=481.78): C, 59.83; H, 7.39; N, 8.72; Cl, 8.28. Found: C, 59.77, H, 7.02; N, 8.61, Cl, 8.29.

EXAMPLE 64 1,1-dimethylethyl [1R-methyl-2-oxo-2-[(3-phenyl-2E-propenyl)amino]ethyl]carbamate ##STR73## (Boc-(D)Ala-NHCH₂ (CH)₂ Ph)

The title compound was prepared by the method of Example 1 using phenylallylamine in place of 6-aminohexanoic acid methyl ester and one equivalent less of NMM.

NMR shift of the (D)Ala methyl=1.36δ (CDCl₃).

Analysis Calcd. for C₁₇ H₂₄ N₂ O₃ ·1/2H₂ O (MW=313.40): C, 65.15; H, 8.04; N, 8.94. Found: C, 65.39; H, 7.81; N, 9.18.

EXAMPLE 65 αR-amino-N-(3-phenyl-2E-propenyl)propanamide ##STR74## ((D)Ala-NHCH₂ (CH)₂ Ph)

The title compound of Example 64 was prepared by the method of Example 2 from the title product of Example 64 to produce the HCl salt. The free base was formed and isolated by the method of Example 44.

NMR shift of the (D) Ala methyl=1.35δ (CDCl₃).

EXAMPLE 66 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-(3-phenyl-2E-propenyl)-D-alaninamide ##STR75## (Boc-(DL)2,6Me₂ Tyr-(D)Ala-NHCH₂ (CH)₂ Ph)

The title compound was prepared by the method of Example 45 using the product of Example 65 instead of the product of Example 44. The diastereomers were separated by LPC on Porasil eluting with 1.4% MeOH/CHCl₃.

Diastereomer DF:

NMR shift of the (D Ala methyl=1.24δ (DMSOd₆).

Diastereomer UF:

NMR shift of the (D)Ala methyl=1.08δ (CDCl₃).

EXAMPLE 67 2,6-dimethyltyrosyl-N-(3-phenyl-2E-propenyl)-D-alaninamide, monohydrochloride DF isomer ##STR76## ((D)2,6Me₂ Tyr-(D)Ala-NHCH₂ (CH)₂ Ph·HCl)

The title product was obtained from the DF-diastereomer of Example 66 by the method of Example 6.

Optical rotation [α]_(D) -78.8°; -293.5° (365) MeOH.

NMR shift of the (D) Ala methyl=1.20δ (DMSOd₆).

Analysis Calcd. for C₂₃ H₂₉ N₃ O₃ ·HCl·1/2C₂ H₄ O₂ (MW=461.99): C, 62.37; H, 6.98; N, 9.09; Cl, 7.67. Found: C, 62.27; H, 6.93; N, 8.89; Cl, 7.86.

EXAMPLE 68 2,6-dimethyltyrosyl-N-(3-phenyl-2E-propenyl)-D-alaninamide, monohydrochloride UF isomer ##STR77## (2,6Me₂ Tyr-(D)Ala-NHCH₂ (CH)₂ Ph·HCl)

The title product was obtained from the UF-diastereomer from Example 66 by the method of Example 6.

Optical rotation [α]_(D) +69.2°; +257.2° (365) CH₃ OH.

NMR shift of the (D)Ala methyl=0.99δ (DMSOd₆).

Analysis Calcd. for C₂₃ H₂₉ N₃ O₃ ·HCl·1/2H₂ O (MW=440.97): C, 62.65; H, 7.09; N, 9.53; Cl, 8.04. Found: C, 62.93; H, 6.93; H, 9.18; Cl, 7.93.

EXAMPLE 69 phenylmethyl [2-[(3,3-diphenylpropyl)amino]-1R-methyl-2-oxoethyl]carbamate ##STR78## The title compound was made by the method of Example 8 where 3,3-diphenylpropyl amine was substituted for the NH2Ad·HCl using one less equivalent of NMM.

NMR shift of the (D)Ala methyl=1.27δ (CDCl₃).

EXAMPLE 70 αR-amino-N-(3,3-diphenylpropyl)propanamide ##STR79## ((D)Ala-NH(CH₂)₂ CH(Ph)₂)

The title compound was prepared by the method of Example 9 substituting the product of Example 69 for the product of Example 8.

NMR shift of the (D)Ala methyl=1.27δ (CDCl₃).

EXAMPLE 71 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-(3,3-diphenylpropyl)-D-alaninamide ##STR80## (Boc-(DL)2,6-Me₂ Tyr-(D)Ala-NH(CH₂)₂ CH(Ph)₂)

The title product was prepared by the method of Example 45 using the product of Example 71 instead of the product of Example 44. The diastereomers were separated by LPC on Porasil eluting with 1%-5% isopropylalcohol/trichloro-trifluoroethane.

Diastereomer DF:

NMR shift of the (D)Ala Methyl=1.19δ (DMSOd₆).

Diastereomer UF:

NMR shift of the (D)Ala methyl=0.98δ (DMSOd₆).

EXAMPLE 72 2,6-dimethyltyrosyl-N-(3,3-diphenylpropyl)-D-alaninamide, monohydrochloride DF isomer ##STR81## ((D)2,6Me₂ Tyr-(D)Ala-NH(CH₂)₂ CH(Ph)₂ ·HCl)

The title product was obtained from DF diastereomer of Example 71 by the method of Example 6.

Optical rotation [α]_(D) -58.6°; -198.1° (365) CH₃ OH.

NMR shift of the (D)Ala methyl=1.27δ (CD₃ OD).

Analysis Calcd. for C₂₉ H₃₅ N₃ O₃ ·HCl·1/2H₂ O (MW=510.08): C, 67.10; H, 7.18; N, 8.10; Cl, 6.83. Found: C, 67.12; H, 6.98; N, 8.09; Cl, 6.86.

EXAMPLE 73 2,6-dimethyltyrosyl-N-(3,3-diphenylpropyl)-D-alaninamide, monohydrochloride UF isomer ##STR82## (2,6Me₂ Tyr-(D)Ala-NH(CH₂)₂ CH(Ph)₂ ·HCl)

The title product was obtained from the UF-Diastereomer of Example 71 by the method of Example 6.

Optical rotation [α]_(D) +97.8°; +360.0° (365) CH₃ OH.

NMR shift the (D)Ala methyl=1.02δ (CD₃ OD).

Analysis Calcd. for C₂₉ H₃₅ N₃ O₃ ·HCl·1/2H₂ O (MW=510.08): C, 67.10; H, 7.18; N, 8.10; Cl, 6.83. Found: C, 66.70; H, 6.94; N, 8.05; Cl, 6.85.

EXAMPLE 74 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-[3-(3-pyridinyl)-2E-propenyl]-D-alaninamide ##STR83## (Boc(DL)2,6-Me₂ Tyr-(D)Ala-NHCH₂ (CH)₂ -3Pyr)

The title product was prepared by the method of Example 18 using the DL mixture of diastereomers from the product of Example 16 and 3-(3-pyridinyl)-2E-propen-1-amine. The reaction product was purified by PLC on Porasil eluting with 10/45/45 isopropylalcohol/trichloro-trifluoro-ethane/CH₂ Cl₂ to give the product mixture of diastereomers.

EXAMPLE 75 2,6-dimethyl-DL-tyrosyl-N-[3-(3-pyridinyl)-2E-propenyl]-D-alaninamide, dihydrochloride ##STR84## ((DL)2,6Me₂ Tyr-(D)Ala-NHCH₂ (CH)₂ -3Pyr·2HCl)

The title product was prepared from the diastereomeric mixture of Example 74 by the method of Example 6.

NMR shift for (D)Ala methyls=1.09 and 1.34δ (CD₃ OD).

Analysis Calcd. for C₂₂ H₂₈ N₄ O₃ ·2HCl·CH₃ CO₂ H·3/4H₂ O (MW 542.98): C, 53.09; H, 6.59; N, 10.32; Cl, 13.06. Found: C, 53.34; H, 6.22; N, 10.11; Cl, 12.74.

EXAMPLE 76 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-[3-(3-pryidinyl)propyl]-D-alaninamide ##STR85## (Boc-(DL)2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ -3Pyr)

The title product was prepared by the Method of Example 18 using the product diastereomeric mixture from Example 16 and 3-pyridinepropanamine. The diastereomers were separated by PLC on Porasil using 2% to 2.3% MeOH/CH₂ Cl₂.

Diastereomer DF:

nmr shift of the (D)Ala methyl=1.30δ (CDCl₃).

Diastereomer UF:

nmr shift of the (D)Ala methyl=1.06δ (CDCl₃).

EXAMPLE 77 2,6-dimethylthyrosyl-N-[3-(3-pyridinyl)propyl]-D-alaninamide, dihydrochloride DF isomer ##STR86## ((D)2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ -3Pyr·HCl)

The title product was obtained from the DF diastereomer of Example 76 by the method of Example 6.

Optical rotation [α]_(D) -33.3°; -139.8° (365) MeOH.

NMR shift for the (D)Ala methyl=1.30δ (CD₃ OD).

Analysis Calcd. for C₂₂ N₃₀ N₄ O₃ ·2HCl·CH₃ CO₂ H (MW 531.49): C, 54.23; H, 6.82; N, 10.54; Cl, 13.34. Found: C, 54.02; H, 6.87; N, 10.46; Cl, 13.31.

EXAMPLE 78 2,6-dimethyltyrosyl-N-[3-(3-pyridinyl)propyl]-D-alaninamide, dihydrochloride UF isomer ##STR87## (2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ -3Pyr·2HCl)

The title product was obtained from the UF diastereomer of Example 76 by the method of Example 6.

Optical rotation [α]_(D) +54.9°; +196.0° (365) MeOH.

NMR shift for the (D)Ala methyl=1.06δ (CD₃ OD).

Analysis Calcd. for C₂₂ H₃₀ N₄ O₃ ·2HCl·CH₃ CO₂ H (MW=531.49): C, 54.23; H, 6.82; N, 10.54; Cl, 13.34. Found: C, 54.61; H, 6.99; N, 10.50; Cl, 13.36.

EXAMPLE 79 1,1-dimethylethyl [1R-methyl-2-oxo-2-[[3-(5-pyrimidinyl)-2E-propenyl]amino]ethyl]carbamate ##STR88## (Boc-(D)Ala-NHCH₂ (CH)₂ -5-Pyrm)

The title compound was prepared by the method of Example 1 using 3-(5-pyrimidinyl)-2E-propen-1-amine instead of 6-amino hexanoic acid methyl ester and one equivalent less of NMM. NMR shift of the (D)Ala methyl=1.38δ (CDCl₃).

EXAMPLE 80 αR-amino-N-[3-(5-pyrimidinyl)-2E-propenyl]propanamide, dihydrochloride ##STR89## ((D)Ala-NHCH₂ (CH)₂ -5-Pyrm·2HCl)

The title product was prepared by deblocking the product of Example 79 by the method of Example 2 to produce the title dihydrochloride salt.

NMR shift of the (D)Ala methyl=1.62δ (D₂ O).

Analysis Calcd. for C₁₀ H₁₄ N₄ O·2HCl·1/4H₂ O (MW=283.67): C, 42.34; H, 5.86; N, 19.75; Cl, 24.99. Found: C, 42.46; H, 5.62; N, 19.38, Cl, 24.78.

EXAMPLE 81 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-[3-(5-pyrimidinyl)-2E-propenyl]-D-alaninamide ##STR90## (Boc-(DL)2,6-Me₂ Tyr-(D)Ala-NHCH₂ (CH)₂ -5Pyrm)

The title mixture of diastereomers were prepared by the method of Example 45 using the free base of the product of Example 80 produced by the method of Example 44 instead of the product of Example 44. The diastereomers were separted by PLC on porasil eluting with 3.3% MeOH/CH₂ Cl₂.

Diastereomer UF:

NMR shift of the (D)Ala methyl=1.39δ (CD₃ OD).

Diastereomer DF:

NMR shift of the (D)Ala methyl=1.13δ (CD₃ OD).

EXAMPLE 82 2,6-dimethyltyrosyl-N-[3-(5-pyrimidinyl)-2E-propenyl]-D-alaninamide, hydrochloride DF isomer ##STR91## ((D)2,6Me₂ Tyr-(D)Ala-NHCH₂ (CH)₂ -5Pyrm·HCl)

The title product was prepared by the method of Example 6 using the DF diastereomer of Example 81.

Optical rotation [α]_(D) -54.5°; -163.6° (365) MeOH.

NMR shift of the (D)Ala methyl=1.20δ (DMSOd₆).

Analysis Calcd. for C₂₁ H₂₇ N₅ O₃ ·13/4HCl·3/4CH₃ CO₂ H·3/4H₂ O (MW=519.84): C, 51.99; H, 6.45; N, 13.47; Cl, 11.94. Found: C, 52.28; H, 6.38; N, 13.64; Cl, 12.04.

EXAMPLE 83 2,6-dimethyltyrosyl-N-[3-(5-pyrimidinyl)-2E-propenyl]-D-alaninamide, hydrochloride UF isomer ##STR92## (2,6Me₂ Tyr-(D)Ala-NHCH₂ (CH)₂ -5Pyrm·HCl)

The title product was prepared by the method of Example 6 using the UF diastereomer of Example 81.

Optical rotation [α]_(D) +56.0°; +102.2° (365) MeOH.

NMR shift of the (D)Ala methyl=0.94δ (DMSOd₆).

Analysis Calcd. for C₂₁ H₂₇ N₅ O₃ ·13/4HCl·3/4CH₃ CO₂ H3/4H₂ O (MW=519.84): C, 51.99; H, 6.45; N, 13.47; Cl, 11.94. Found: C, 51.60; H, 6.41; N, 13.59; Cl, 12.09.

EXAMPLE 84 4-(3-amino-1E-propenyl)benzonitrile ##STR93##

The title compound was prepared from 4-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-1E-propenyl]benzonitrile using the method of Example 48.

EXAMPLE 85 1,1-dimethylethyl [2-[[3-(4-cyanophenyl)-2E-propenyl]amino]-1R-methyl-2-oxoethyl]carbamate ##STR94## (Boc-(D)Ala-NH-CH₂ -CH═CH-(4-CN)Ph)

The title compound was prepared by the method of Example 1 using the title material from Example 84 in place of 6-aminohexanoic acid methyl ester hydrochloride and one equivalent less of NMM.

NMR shift of the (D)Ala methyl=1.39δ (CDCl₃).

EXAMPLE 86 αR-amino-N-[3-(4-cyanophenyl)-2E-propenyl]propanamide, monohydrochloride ##STR95## ((D)Ala-NHCH₂ (CH)₂ -(4-CN)Ph·HCl)

The title compound was prepared by the method of Example 2 from the title product of Example 85.

NMR shift for the (D)Ala methyl=1.43δ (CD₃ OD).

Analysis Calcd. for C₁₃ H₁₅ N₃ O·HCl·3/8H₂ O (MW=272.50): C, 57.30; N, 6.20; N, 15.42; Cl, 13.01. Found: C, 57.67; H, 6.16; N, 15.41; Cl, 12.62.

EXAMPLE 87 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-[3-(4-cyanophenyl)-2E-propenyl]-D-alaninamide ##STR96## (Boc-(DL)2,6Me₂ Tyr-(D)Ala-NHCH₂ (CH)₂ -(4-CN)Ph)

The title mixture of diastereomers were prepared by the method of Example 45 using the free base of the product of Example 86 produced by the method of Example 44 instead of the product of Example 44.

The diastereomers were separated by PLC on porasil eluting with 3% MeOH/CH₂ Cl₂.

Diastereomer DF:

NMR shift of the (D)Ala methyl=1.26δ (DMSOd₆)

Diastereomer UF:

NMR shift of the (D)Ala methyl=1.12δ (CDCl₃).

EXAMPLE 88 2,6-dimethyltyrosyl-N-[3-(4-cyanophenyl)-2E-propenyl]-D-alaninamide, monohydrochloride DF isomer ##STR97## ((D)2,6Me₂ Tyr-(D)Ala-NHCH₂ (CH)₂ -(4-CN)Ph·HCl)

The title product was prepared by the method of Example 6 using the DF diastereomer of Example 87.

Optical rotation [α]_(D) -82.9°; -345.7° (365) MeOH.

NMR shift for the (D)Ala methyl=1.32δ (CH₃ OD).

Analysis Calcd. for C₂₄ H₂₈ N₄ O₃ ·HCl·CH₃ CO₂ H (MW=517.07): C, 60.40; H, 6.43; N, 10.84; Cl, 6.86. Found: C, 60.11; H, 6.39; N, 11.01; Cl, 7.24.

EXAMPLE 89 2,6-dimethyltyrosyl-N-[3-(4-cyanophenyl)-2E-propenyl]-D-alaninamide, monohydrochloride UF isomer ##STR98## (2,6Me₂ Tyr-(D)Ala-NHCH₂ (CH)₂ -(4-CN)Ph·HCl)

The title product was prepared by the method of Example 6 using the UF diastereomer of Example 87.

Optical rotation [α]_(D) +62.6°; +238.3° (365) MeOH.

NMR shift for the (D)Ala methyl=1.08δ (CD₃ OD).

Analysis Calcd. for C₂₄ H₂₈ N₄ O₃ ·HCl·CH₃ CO₂ H (MW=517.07): C, 60.40; H, 6.43; N, 10.84; Cl, 6.86. Found: C, 60.65; H, 6.55; N, 11.15; Cl, 7.24.

EXAMPLE 90 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-D-tyrosyl-N-[3-(4-cyanophenyl)propyl]-D-alaninamide ##STR99## (Boc-(D)2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ (4-CN)Ph)

The title product was obtained by hydrogenation of the DF diastereomer from Example 87 in THF at ambient temperature and pressure using 5% Pd/C as catalyst. The catalyst was removed by filtration and the solvent was removed by distillation. The resultant product was used without further purification

EXAMPLE 91 2,6-dimethyltyrosyl-N-(4-cyanophenyl)propyl]-D-alaninamide, monohydrochloride DF isomer ##STR100## ((D)2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ (4-CN)Ph·HCl)

The title compound was prepared from the title compound of Example 90 using the procedure of Example 6.

Optical rotation [α]_(D) -67.9°; -246.5° (365) MeOH

NMR shift of the (D)Ala methyl=1.26δ (CD₃ OD).

Analysis Calcd. for C₂₄ H₃₀ N₄ O₃ ·HCl·1/4C₄ H₈ O₂ H₂ O (MW 499.03): C, 60.17; H, 7.07; N, 11.23; Cl, 7.10. Found: C, 60.01; H, 6.67; N, 11.07; Cl, 7.18.

EXAMPLE 92 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyltyrosyl-N-[3-(4-cyanophenyl)propyl]-D-alaninamide, isomer UF isomer ##STR101## (Boc-2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ (4-CN)Ph)

The title product was prepared from the UF diastereomer from Example 87 using the method of Example 90.

EXAMPLE 93 2,6-dimethyltyrosyl-N-[3-(4-cyanophenyl)propyl]-D-alaninamide, monohydrochloride UF isomer ##STR102## (2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ (4-CN)Ph·HCl)

The title compound was prepared from the title product of Example 92 using the method of Example 6.

Optical rotation [α]_(D) +92.7°; +349.3° (365) MeOH.

NMR shift for the (D)Ala methyl=1.04δ (CD₃ OD).

Analysis Calcd. for C₂₄ H₃₀ N₄ O₃ ·1/4C₄ H₈ O₂ ·3/4H₂ O (MW=494.53): C, 60.71; H, 7.03; N, 11.33; Cl, 7.17. Found: C, 60.71; H, 6.85; N, 10.99; Cl, 7.11.

EXAMPLE 94 phenylmethyl [2-[[3-(1,3-benzodioxol-5-yl)-2E-propenyl]amino]-1R-methyl-2-oxoethyl]carbamate ##STR103## (Z-(D)Ala-NH-CH₂ -(CH)₂ -(3,4-CH₂ O₂)Ph)

The title compound was prepared by the method of Example 8 where 3-(1,3-benzodioxol-5-yl)-2E-propen-1-amine is substituted for NH₂ 2Ad·HCl using one less equivalent of NMM. The product was purified using PLC on Woelm® Silica eluting with 2/97.8/0.2 EtOH/CH₂ Cl₂ /NH₄ OH.

EXAMPLE 95 R-amino-N-[3-(1,3-benzodioxol-5-yl)propyl]propanamide ##STR104## ((D)Ala-NH(CH₂)₃ (3,4-CH₂ O₂)Ph)

The title product was obtained by hydrogenating the product of Example 94 in THF at 60 psi and ambient temperature using 5% Pd/C as a catalyst. The resultant residual oil after filtering off the catalyst and removing the solvent under reduced pressure was used without further purification. NMR shift for the (D)Ala methyl=1.30δ (CDCl₃).

EXAMPLE 96 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-[3-(1,3-benzodioxol-5-yl)propyl]-D-alaninamide ##STR105## (Boc-(DL)2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ (3,4CH₂ O₂)Ph)

The title mixture of diastereomers were prepared by the method of Example 45 using the product of Example 95 instead of the product of Example 44. The diastereomers were separated by gradient PLC on Woelm® Silica eluting with 1.5 to 3.5% MeOH/CHCl₃.

Diastereomer DF:

NMR shift of the (D) Ala methyl=1.31δ (CD₃ OD).

Diastereomer UF:

NMR shift of the (D) Ala methyl=1.04δ (CD₃ OD).

EXAMPLE 97 2,6-dimethyltyrosyl-N-[3-(1,3-benzodioxol-5-yl)propyl]-D-alaninamide, monohydrochloride DF isomer ##STR106## ((D)2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ (3,4CH₂ O₂)Ph·HCl)

The title compound was prepared from the DF diastereomer of the title product of Example 96 using the method of Example 6.

Optical rotation [α]-57.1°; -214.3° (365) MeOH.

NMR shift of the (D)Ala methyl=1.25δ (CD₃ OD).

Analysis Calcd. for C₂₄ H₃₁ N₃ O₅ ·HCl·1/8C₄ H₈ O₂ ·7/16H₂ O (MW=496.89): C, 59.22; H, 6.87; N, 8.46; Cl, 7.14. Found: C, 59.12; H, 6.82; N, 8.06; Cl, 7.54.

EXAMPLE 98 2,6-dimethyltyrosyl-N-[3-(1,3-benzodioxol-5-yl)propyl]-D-alaninamide, monohydrochloride UF isomer ##STR107## (2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ (3,4CH₂ O₂)Ph·HCl)

The title compound was prepared from the UF diastereomer of the title product of Example 96 using the method of Example 6.

Optical rotation [α]_(D) +94.7°; +340.1° (365) CH₃ OH.

NMR Shift of the (D)Ala methyl=1.02δ (CD₃ OD).

Analysis Calcd. for C₂₄ H₃₁ N₃ O₅ ·1/8C₄ H₈ O₂ ·HCl·1/4H₂ O (MW=493.51): C, 59.63; H, 6.84; N, 8.51; Cl, 7.18. Found: C, 59.51; H, 6.93; N, 8.27; Cl, 7.50.

EXAMPLE 99 phenylmethyl [1R-methyl-2-[(1-methyl-3-phenylpropyl)amino]-2-oxoethyl]carbamate ##STR108## (Z-(D)Ala-NHCH(CH₃)(CH₂)₂ Ph)

The title product was prepared by the method of Example 8 when α-methylbenzenepropanamine was substituted for the N2H₂ Ad·HCl using one less equivalent of NMM. NMR shifts for the methyls of (D)Ala and α methyl PPA=two pairs of doublets; 1.12δ and 1.14δ plus 1.35δ and 1.33δ (CDCl₃).

EXAMPLE 100 αR-amino-N-(1-methyl-3-phenylpropyl)propanamide ##STR109## (D)Ala-NHCHCH₃ (CH₂)₂ Ph)

The title compound was prepared by the method of Example 9 substituting the product of Example 99 for the product of Example 8. The two diastereomers were separated by LPC on Porasil eluting with 1.5/98.4/0.1MeOH/CHCl₃ /NH₄ OH.

Diastereomer DF: [α]_(D) -37.2°; -152.4° (365) CHCl₃.

NMR shift for the (D)Ala methyl and PPA α methyl=1.29δ, J=0.9 Hz and 1.18δ, J=0.9 Hz (CDCl₃) respectively.

Diastereomer UF: [α]_(D) +41.2°; +186.1° (365) CHCl₃.

NMR shift of the (D)Ala methyl and PPA α methyl=1.30δ, J=0.9 Hz and 1.19δ, J=0.9 Hz (CDCl₃).

EXAMPLE 101 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-(1-methyl-3-phenylpropyl)-D-alaninamide, isomer UF ##STR110## (Boc(DL)2,6Me₂ Tyr-(D)Ala-NHCHCH₃ (CH₂)₂ Ph)

The title compounds were prepared from the UF diastereomer of Example 100 instead of the product of Example 44 using the method of Example 45. The UF-diastereomers were separated by LPC on porasil eluting with 1 to 2% MeOH/CH₂ Cl₂. These diastereomers were not purified further.

EXAMPLE 102 2,6-dimethyltyrosyl-N-(1S-methyl-3-phenylpropyl)-D-alaninamide, hydrochloride UF isomer ##STR111## ((D)2,6Me₂ Tyr-(D)Ala-NHCHCH₃ (CH₂)₂ Ph·HCl

The title product was prepared from the diastereomer of Example 101 with the greater TLC Rf using the method of Example 6.

Optical rotation [α]_(D) -41.4°; -184.2° (365) MeOH.

NMR shift for the (D)Ala methyl=1.32δ (CD₃ OD),

NMR shift for the PPA α methyl=1.16δ (CD₃ OD).

Analysis Calcd. for C₂₄ H₃₃ N₃ O₃ ·11/8HCl·1/8C₄ H₈ O₂ ·H₂ O (MW=481.59): C, 61.10; H, 7.77; N, 8.73; Cl, 8.28. Found: C, 60.91; H, 7.45; N, 8.84; Cl, 8.00.

EXAMPLE 103 2,6-dimethyltyrosyl-N-(1S-methyl-3-phenylpropyl)-D-alaninamide, hydrochloride UF isomer ##STR112## (2,6Me₂ Tyr-(D)Ala-NHCH(Me)(CH₂)₂ -Ph)

The title product was prepared from the diastereomer of Example 101 with the lesser TLC Rf using the method of Example 6.

Optical rotation [α]_(D) +111.7°; +421.9° (365) (MeOH).

NMR shift for the (D)Ala methyl=1.06δ CD₃ OD.

NMR shift for the PPA α methyl=1.12δ CD₃ OD.

Analysis Calcd. for C₂₄ H₃₃ N₃ O₃ ·11/8HCl·1/8C₄ H₈ O₂ ·H₂ O (MW=481.59): C, 61.10; H, 7.77; N, 8.73; Cl, 8.28. Found: C, 60.93; H, 7.28; N, 8.74; Cl, 8.00.

EXAMPLE 104 2-[2-(phenylthio)ethyl]-1H-isoindole-1,3(2H)-dione ##STR113##

Potassium phthalimide (5.43 g, 25 mmol) was added to a DMF (50 ml) solution of [(2-bromoethyl)thio]benzene (5,43 g, 25 mmol) and this stirred mixture under N₂ was heated at 90° C. for 2 h. After cooling to room temperature, the reaction was filtered. The solvent was stripped from the filtrate under reduced pressure. The residue, dissolved in CH₂ Cl₂ (100 ml), was filtered, concentrated, and flash chromotographed on a 4 inch column eluting with 1 to 6% EtOAc/toluene to produce 4.9 g of the title product.

Analysis Calcd. for C₁₆ H₁₃ NO₂ S (MW=283.34): C, 67.82; H, 4.62; N, 4.94; S, 11.31. Found: C, 67.92; H, 4.50; N, 5.00; S, 11.59.

EXAMPLE 105 2-(phenylthio)ethanamine ##STR114##

The title material was prepared from the title product of Example 103 by the method of Example 48.

Analysis Calcd. for C₈ H₁₁ NS·H₂ O (MW=171.26): C, 56.10; H, 7.65; N, 8.18; S, 18.72. Found: C, 55.87; H, 7.30; N, 7.84; S, 18.20.

EXAMPLE 106 1,1-dimethylethyl [1R-methyl-2-oxo-2-[[2-(phenylthio)ethyl]amino]ethyl]carbamate ##STR115## (Boc-(D)Ala-NH(CH₂)₂ SPh)

The title compound was prepared by the method of Example 1 using the title material from Example 105 in place of the amine hydrochloride of Example 1. One equivalent less of NMM was also used since the material of Example 105 was the free base. The product was used without further purification.

EXAMPLE 107 αR-amino-N-[2-(phenylthio)ethyl]propanamide, monohydrochloride ##STR116## ((D)Ala-NH(CH₂)₂ SPh·HCl)

The title compound was prepared by the method of Example 2 from the title material of Example 106.

Optical rotation [α]_(D) +54.9° (MeOH).

NMR shift of the (D)Ala methyl=1.47δ (CD₃ OD).

EXAMPLE 108 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-[2-(phenylthio)ethyl]-D-alaninamide ##STR117## (Boc-(DL)2,6Me₂ Tyr-(D)Ala-NH(CH₂)₂ SPh)

The title mixture of diastereomers were prepared and separated by the method of Example 45 using the title material of Example 107 in place of the title amide of Example 44.

EXAMPLE 109 2,6-dimethyltyrosyl-N-[2-(phenylthio)ethyl]-D-alaninamide, monohydrochloride DF isomer ##STR118## ((D)2,6-Me₂ Tyr-(D)Ala-NH(CH₂)₂ SPh·HCl)

The title compound was synthesized from the DF diastereomer of Example 108 by the method of Example 6.

Optical rotation [α]_(D) -64.5° (MeOH).

NMR shift of the (D)Ala methyl=1.13δ (CD₃ OD).

Analysis Calcd. for C₂₂ H₂₉ N₃ SO₃ ·HCl·11/2H₂ O (MW=479.05): C, 55.16; H, 6.94; N, 8.77; Cl, 7.40; S, 6.69. Found: C, 54.94; H, 6.49; N, 7.93; Cl, 7.43; S, 6.34.

EXAMPLE 110 2,6-dimethyltyrosyl-N-[2-(phenylthio)ethyl]-D-alaninamide, monohydrochloride UF isomer ##STR119## (2,6-Me₂ Tyr-(D)Ala-NH(CH₂)₂ SPh·HCl)

The title compound was prepared from the UF diastereomers of Example 108 by the method of Example 6.

Optical rotation [α]_(D) +109.5° (MeOH).

NMR shift of the (D)Ala methyl=0.88δ (CD₃ OD).

Analysis Calcd. for C₂₂ H₂₉ N₃ SO₃ ·HCl·H₂ O (MW=470.04): C, 56.22; H, 6.86; N, 8.94; Cl, 7.54; S, 6.82. Found: C, 55.68; H, 6.49; N, 8.64; Cl, 7.94; S, 6.44.

EXAMPLE 111 2-(2-phenoxyethyl)-1H-isoindole-1,3(2H)-dione ##STR120##

The title compound was prepared by the method of Example 104 using phenyl-O-CH₂ CH₂ Cl in place of phenyl-S-CH₂ CH₂ Br.

Analysis Calcd. for C₁₆ H₁₃ NO₃ (MW=267.30): C, 71.90; H, 4.90; N, 5.24. Found: C, 71.81; H, 4.69; N, 4.94.

EXAMPLE 112 2-phenoxyethanamine ##STR121##

The title product was prepared from the title material of Example 111 by the method of Example 48 and used in subsequent reactions without further purification.

EXAMPLE 113 1,1-dimethylethyl [1R-methyl-2-oxo-2-[(2-phenoxyethyl)amino]ethyl]carbamate ##STR122## (Boc-(D)Ala-NH(CH₂)₂ OPh)

The title compound was prepared by the method of Example 1 using the title material from Example 112 in place of the amine hydrochloride of Example 1. One equivalent less of NMM was also used since the material of Example 112 was the free base. The product was used without further purification.

EXAMPLE 114 αR-amino-N-(2-phenoxyethyl)propanamide, monohydrochloride ##STR123## ((D)Ala-NH(CH₂)₂ OPh·HCl)

The title compound was prepared by the method of Example 2 from the title material of Example 113.

Optical rotation [α]_(D) -2.0° (MeOH).

NMR shift of the (D)Ala methyl=1.47δ (CD₃ OD).

Analysis Calcd. for C₁₁ H₁₇ N₂ O₂ Cl (MW=244.72): C, 53.99; H, 7.00; N, 11.45; Cl, 14.49. Found: C, 53.61; H, 6.99; N, 11.17; Cl, 14.43.

EXAMPLE 115 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-(2-phenoxyethyl)-D-alaninamide ##STR124## (Boc-(DL)2,6Me₂ Tyr-(D)Ala-NH(CH₂)₂ OPh)

The title mixture of diastereomers were prepared and separated by the method of Example 45, using the title material of Example 114 in place of the title amide of Example 44.

EXAMPLE 116 2,6-dimethyltyrosyl-N-(2-phenyoxyethyl)-D-alaninamide, hydrochloride DF isomer ##STR125## ((D)2,6Me₂ Tyr-(D)Ala-NH(CH₂)₂ OPh·HCl)

The title compound was synthesized from the DF diastereomer of Example 115 by the method of Example 6.

Optical rotation [α]_(D) -52.5° (CH₃ OH).

NMR shift of the (D)Ala methyl=1.26δ (CD₃ OD).

Analysis Calcd. for C₂₂ H₂₉ N₃ O₄ ·11/8HCl·11/4H₂ O (MW=463.03): C, 57.07; H, 7.10; N, 9.08; Cl, 8.61. Found: C, 56.77; H, 6.73; N, 8.70; Cl, 8.34.

EXAMPLE 117 2,6-dimethyltyrosyl-N-(2-phenoxyethyl)-D-alaninamide, monohydrochloride, isomer UF isomer ##STR126## (2,6Me₂ Tyr-(D)Ala-NH(CH₂)₂ OPh·HCl)

The title compound is synthesized from the UF diastereomer of Example 115 by the method of Example 6.

EXAMPLE 118 2-[3-[4-(dimethylamino)phenyl]propyl]-1H-isoindole-1,3(2H)-dione ##STR127##

The title compound was prepared by hydrogenation of 2-[3-[4-(dimethylamino)phenyl]-2E-propenyl]-qH-isoindole-1,3(2H)-dione in THF at 5 psi and ambient temperature using 5% Pd/C as catalyst. After the reaction mixture was filtered and concentrated, the title compound was used without further purification.

EXAMPLE 119 4-(dimethylamino)benzenepropanamine ##STR128##

The title compound was prepared from the product of Example 118 using the method of Example 48.

EXAMPLE 120 phenylmethyl [2-[[3-[4-(dimethylamino)phenyl]propyl]amino]-1R-methyl-2-oxoethyl]carbamate ##STR129## (Z-(D)Ala-NH(CH₂)₃ -(4-Me₂ N)Ph)

The title compound was prepared by the method of Example 8 where the product of Example 119 was substituted for the 6-amino hexanoic acid methyl ester. The title compound was purified by PLC on Woelm® silical gel eluting with 2/98/0.2 EtOH/CH₂ Cl₂ /NH₄ OH.

NMR shift of the (D)ala methyl=1.32δ (CDCl₃).

EXAMPLE 121 αR-amino-N-[3-[4-(dimethylamino)phenyl]propyl]propanamide ##STR130## ((D)Ala-NH(CH₂)₃ -(4Me₂ N)Ph)

The title compound was prepared by hydrogenation of the product from Example 120 in THF at ambient temperature and 60 psi using 5% Pd/C as catalyst. The reaction mixture was filtered and concentrated. The resultant title product oil was used without further purification.

NMR shift of the (D)Ala methyl=1.28δ (CDCl₃).

EXAMPLE 122 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-[3-[4-(dimethylamino)phenyl]propyl]-D-alaninamide ##STR131## (Boc-(DL)2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ -(4-Me₂ N)Ph)

The title compound was prepared by the method of Example 45 using the product of Example 121 in place of the C-terminal amino acid amide used in Example 45. The reaction mixture of diastereomers was purified by PCL on Porasil eluting with 5/95: MeOH/CH₂ Cl₂.

EXAMPLE 123 2,6-dimethyl-DL-tyrosyl-N-[3-[4-(dimethylamino)-phenyl]propyl]-D-alaninamide, dihydrochloride ##STR132## ((DL)2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ -(4-Me₂ N)Ph·HCl)

The title compound was prepared from the diastereomeric mixture of Example 122 by the method of Example 6.

NMR shift of the (D)Ala methyls=0.87δ+1.14δ (DMSOd₆).

Optical rotation [α]_(D) +29.0°; +91.0° (365) MeOH.

Analysis calcd. for C₂₅ H₃₆ N₄ O₃ ·2HCl·11/2H₂ O (MW=538.28): C, 55.78; H, 7.63; N, 10.41, Cl, 13.17. Found: C, 56.06; H, 7.23; N, 10.10, Cl, 12.81.

EXAMPLE 124 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-(1-methyl-3-phenylpropyl)-D-alaninamide DF isomer ##STR133## (Boc-(DL)2,6Me₂ Tyr-(D)Ala-NHCHCH₃ (CH₂)₂ Ph)

The title compounds were prepared from the DF diastereomer of Example 100 instead of the product of Example 44 using the method of Example 45.

EXAMPLE 125 2,6-dimethyl-DL-tyrosyl-N-(1-methyl-3-phenylpropyl)-D-alaninamide hydrochloride DF isomer ##STR134## ((DL)2,6Me₂ Tyr-(D)Ala-NHCHCH₃ (CH₂)₂ Ph·HCl)

The title products were prepared from the product of Example 124 using the method of Example 6.

Optical rotation [α]_(D) +33.5°; +108.8° (365) MeOH.

NMR shift of the (D)Ala methyl=1.31+1.39δ (CDCl₃).

NMR shift of the PPA α methyl=1.17δ (CDCl₃).

Analysis calcd. for C₂₄ H₃₃ N₃ O₃ (MW=411.55): C, 70.04; H, 8.08; N, 10.21. Found: C, 69.97; H, 7.92; N, 10.17.

EXAMPLE 126 methyl 4-[3-[[1-oxo-2R-[[(phenylmethoxy)carbonyl]amino]propyl]amino]-1E-propenyl]benzoate ##STR135## (Z-(D)Ala-NHCH₂ (CH)₂ -(4-CO₂ Me)Ph)

The title compound was prepared by the method of Example 8 where methyl 4-(3-amino-1E-propenyl)benzoate was substituted for the NH₂ 2Ad·HCl using one less equivalent of NMM.

EXAMPLE 127 methyl 4-[3-[(2R-amino-1-oxopropyl)amino]propyl]benzoate ##STR136## (D)Ala-NHCH₂ (CH)₂ -(4-CO₂ Me)Ph)

The title product was obtained by hydrogenation of the product of Example 126 using the method described in Example 95. NMR shift of the (D)Ala methyl=1.31δ (CDCl₃).

EXAMPLE 128 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-[3-[4-methoxycarbonyl)phenyl]propyl]-D-alaninamide. ##STR137## (Boc-(DL)2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ (4-CO₂ Me)Ph)

The title mixture of diastereomers was prepared by the method of Example 45 using the product of Example 127 as the C-terminal unit. The reaction mixture was purified by PLC on Woelm® silica eluting with 2/97.85/0.15 MeOH/CH₂ Cl₂ /NH₄ OH.

EXAMPLE 129 2,6-dimethyl-DL-tyrosy-N-[3-[4-(methoxycarbonyl)phenyl]propyl-D-alaninamide, monohydrochloride. ##STR138## ((DL)2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ (4-CO₂ Me)Ph·HCl)

The title compound was prepared from the diastereomer mixture of Example 128 using the method of Example 6.

NMR shift of the (D)Ala methyl=1.05δ+1.27δ (CD₃ OD).

Optical rotation [α]_(D) +20.0°; +74.3° (365) MeOH.

Analysis Calcd. for C₂₅ H₃₃ N₃ O₅ ·HCl·1/2H₂ O (MW=501.02): C, 59.93; H, 7.04; N, 8.39; Cl, 7.08. C, 59.85; H, 7.07; N, 8.39; Cl, 7.10.

EXAMPLE 130 2-[3-(5-pyrimidinyl)propyl]-1H-isoindole-1,3(2H)-dione ##STR139##

The title compound was prepared by hydrogenation of 2-[3-(5-pyrimidinyl)-2E-propenyl]-1H-isoindole-1,3(2H)-dione using the method of Example 118.

EXAMPLE 131 5-pyrimidinepropanamine ##STR140##

The title compound was prepared from the product of Example 130 using the method of Example 48.

EXAMPLE 132 ##STR141## (Boc-(DL)2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ -5pyrm)

The title compound was prepared from the product of Example 131 using the method of Example 18. The diastereomers were separated by gradient PLC on Woelm® silica eluting with MeOH/CH₂ Cl₂ /NH₄ OH ratios of 2/97.85/0.15 to 5/94.6/0.40.

Diastereomer DF:

NMR shift of the (D)Ala methyl=1.21δ (DMSOd₆).

Diastereomer UF:

NMR shift of the (D)Ala methyl=0.98δ (DMSOd₆).

EXAMPLE 133 2,6-dimethyl-D-tyrosyl-N-[3-(5-pyrimidinyl)propyl]-D-alaninamide, dihydrochloride DF isomer ##STR142## (2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ -5 pyrm·2HCl)

The title product was prepared from the DF-diastereomer of Example 132 by the method of Example 6.

NMR shift of the (D)Ala methyl=1.15δ (DMSOd₆).

Optical rotation [α]_(D) -62.3°; -209.3° (365) MeOH.

Analysis calcd. for C₂₁ H₂₉ N₅ O₃ ·2HCl·11/4H₂ O (MW=494.94): C, 50.96; H, 6.82; N, 14.15; Cl, 14.32. Found: C, 50.76; H, 6.66; N, 14.19; Cl, 14.39.

EXAMPLE 134 2,6-dimethyl-L-tyrosyl-N-[3-(5-pyrimidinyl)propyl]-D-alaninamide, dihydrochloride UF isomer ##STR143## (2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ -5 pyrm·2HCl)

The title compound was prepared from the UF-diastereomer of Example 133 by the method of Example 6.

NMR shift of the (D)Ala methyl=1.04δ (CD₃ OD).

Optical rotation [α]_(D) +89.5°; +332.4° (365) MeOH.

Analysis calcd. for C₂₁ H₂₉ N₅ O₃ ·2HCl·5/8H₂ O (MW=483.68): C, 52.15, H, 6.72, N, 14.48, Cl, 14.66. Found: C, 52.45, H, 6.54, N, 14.56, Cl, 14.24.

EXAMPLE 135 2-[3-(4-fluorophenyl)-2E-propenyl]-1H-isoindole-1,3(2H)-dione ##STR144##

N-Allylphthalimide (13.9 g, 74.3 mmol), 1-fluoro-4-iodobenzene (15.0 g, 67.6 mmol) triethylamine (15.0 g, 148 mmol) and Pd(OAc)₂ (152 mg) were heated at 104° in a glass bomb with shaking for 18 h under an inert atmosphere. The reaction mixture was dissolved in hot acetonitrile. The catalyst was removed by filtration and the filtrate cooled to 0°. The precipitated white solid product was filtered off and dried under vacuum. This title material (12.55 g) was used without further purification.

EXAMPLE 136 3-(4-fluorophenyl)-2E-propen-1-amine ##STR145##

The title compound was prepared from the product of Example 135 using the method of Example 48.

EXAMPLE 137 phenylmethyl [2-[[3-(4-fluorophenyl)propyl]amino]-1R-methyl-2-oxoethyl]carbamate ##STR146## (Z-(D)Ala-NH(CH₂)₃ (4-F)Ph)

The title compound was prepared from the product of Example 136 using the method of Example 8. The title compound was purified by PLC on Porasil eluting with 20/80 EtOAc/CH₂ Cl₂.

NMR shift of the (D)Ala methyl=1.38δ (DMSOd₆).

EXAMPLE 138 αR-amino-N-[3-(4-fluorophenyl)propyl]propanamide ##STR147## ((D)Ala-NH(CH₂)₃ (4-F)Ph)

The title compound was prepared by hydrogenation of the product from Example 137 using the method of Example 121.

NMR shift of the (D)Ala methyl=1.32δ (CDCl₃).

EXAMPLE 139 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-[3-(4-fluorophenyl)propyl]-D-alaninamide ##STR148## (Boc-(DL)2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ (4-F)Ph)

The title diastereomers were prepared by the method of Example 45 using the product of Example 138 as the C-terminal unit.

The diastereomers were separated by PLC on Woelm® silica eluting with 2.5/97.3/0.2 MeOH/CH₂ Cl₂ /NH₄ OH.

Diastereomer DF:

NMR shift of the (D)ala methyl=1.18δ (DMSOd₆).

Diastereomer UF:

NMR shift of the (D)ala methyl=0.99δ (DMSOd₆).

EXAMPLE 140 2,6-dimethyl-D-tyrosyl-N-[3-(4-fluorophenyl)propyl]-D-alaninamide, hydrochloride DF isomer ##STR149## (2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ (4-F)Ph·HCl)

The title compound was prepared from the DF-diastereomer of Example 139 by the method of Example 6.

NMR shift of the (D)ala methyl=1.16δ (DMSOd₆).

Optical rotation [α]_(D) -52.4°; -181.9° (365) MeOH.

Analysis calcd. for C₂₃ H₃₀ FN₃ O₃ ·11/8HCl·1/4H₂ O (MW=461.03): C, 59.92; H, 6.91; N, 9.11; Cl, 8.65; F, 4.12. Found: C, 59.81; H, 6.81; N, 9.02; Cl, 8.62; F, 4.09.

EXAMPLE 141 2,6-dimethyl-L-tyrosyl-N-[3-(4-fluorophenyl)propyl]-D-alaninamide, hydrochloride UF isomer ##STR150## (2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ (4-F)Ph·HCl)

The title compound was prepared from the UF-diastereomer of Example 139 by the method of Example 6.

NMR shift of the (D)Ala methyl=0.90δ (DMSOd₆).

Optical rotation [α]_(D) +99.5°, +377.6° (365) MeOH.

Analysis calcd. for C₂₃ H₃₀ FN₃ O₃ ·11/8HCl·3/4H₂ O (MW=470.04): C, 58.77; H, 7.00; N, 8.94; Cl, 8.49; F, 4.04. Found: C, 59.01; H, 6.83; N, 8.65; Cl, 8.09; F, 4.45.

EXAMPLE 142 phenylmethyl [2-[[3-(4-hydroxyphenyl)-2E-propenyl]amino]-1R-methyl-2-oxoethyl]carbamate ##STR151## (Z-(D)Ala-NHCH₂ (CH)₂ -(4-OH)Ph)

The title compound was prepared by the method of Example 8 where 4-(3-amino-1E-propenyl)phenol was substituted for the NH₂ 2Ad·HCl using one less equivalent of NMM.

EXAMPLE 143 αR-amino-N-[3-(4-hydroxyphenyl)propyl]propanamide ##STR152## ((D)Ala-NH(CH₂)₃ (4-OH)Ph)

The title compound was obtained by hydrogenation of the product of Example 142 using the method of Example 95.

EXAMPLE 144 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-[3-(4-hydroxyphenyl)propyl]-D-alaninamide ##STR153## (Boc(DL)2,6Me₂ Tyr(D)Ala-NH(CH₂)₃ (4-OH)Ph)

The title diastereomers were prepared by the method of Example 45 using the product of Example 143 as the C-terminal unit. The diastereomers were separated by PLC on Woelm® silica eluting with 5/94.6/0.4; MeOH/CHCl₃ /NH₄ OH.

Diastereomer DF:

NMR shift of the (D)Ala methyl=1.18δ (DMSOd₆)

Diastereomer UF:

NMR shift of the (D)Ala methyl=1.00δ (DMSOd₆)

EXAMPLE 145 2,6-dimethyl-D-tyrosyl-N-[3-(4-hydroxyphenyl)propyl]-D-alaninamide, hydrochloride DF isomer ##STR154## (2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ (4-OH)Ph·HCl)

The title compound was prepared from the DF diastereomer of Example 144 by the method of Example 6.

NMR shift of the (D)ala methyl=1.15δ (DMSOd₆).

Optical rotation [α]_(D) -47.6°, -190.5° (365) MeOH.

Analysis calcd. for C₂₃ H₃₁ N₃ O₄ ·11/8HCl·3/4H₂ O (MW=468.05): C, 59.02; H, 7.24; N, 8.98; Cl, 8.52. Found: C, 58.64; H, 6.84; N, 8.85; Cl, 8.12.

EXAMPLE 146 2,6-dimethyl-L-tyrosyl-N-[3-(4-hydroxyphenyl)propyl]-D-alaninamide, hydrochloride UF isomer ##STR155## (2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ (4-OH)Ph·HCl)

The title compound was prepared from the UF diastereomer of Example 144 by the method of Example 6.

NMR shift of the (D)Ala methyl=0.86δ (DMSOd₆).

Optical rotation [α]_(D) +95.6°; +363.7° (365) MeOH.

Analysis calcd. for C₂₃ H₃₁ N₃ O₄ ·11/8HCl·H₂ O (MW=472.55): C, 58.46; H, 7.28; N, 8.89; Cl, 8.44. Found: C, 58.84; H, 6.89; N, 8.87; Cl, 8.19.

EXAMPLE 147 phenylmethyl [2-[[2-(9H-fluoren-9-yl)ethyl]amino-1R-methyl-2-oxoethyl]carbamate ##STR156## (Z-(D)Ala-NH(CH₂)₂ -9-Fluorene)

The title compound was prepared by the method of Example 8 where 9H-fluren-9-yl-ethanamine was substituted for the 6-aminohexanoic acid methyl ester. The title compound was purified by PLC on silica gel using 1.5% 2-propanol/CH₂ Cl₂.

EXAMPLE 148 αR-amino-N-[2-(9H-fluoren-9-yl)ethyl]propanamide ##STR157## ((D)Ala-NH(CH₂)₂ -9-Flourene)

The title product was obtained by hydrogenation of the product of Example 147 using the method of Example 9.

EXAMPLE 149 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-[2-(9H-fluoren-9-yl)ethyl]-D-alaninamide ##STR158## (Boc-(DL)2,6Me₂ Tyr-(D)Ala-NH(CH₂)₂ -9-Fluorene)

The title product was prepared by the method of Example 45 using the product of Example 148 as the C-terminal coupling fragment. The diastereomers were separated by PLC on Woelm® silica eluting with 2% to 7% 2-propanol (with 7% NH₄ OH)/toluene.

EXAMPLE 150 2,6-dimethyl-D-tyrosyl-N-[2-(9H-fluoren-9-yl)ethyl]-D-alaninamide, monohydrochloride DF isomer ##STR159## (2,6Me₂ Tyr-(D)Ala-NH(CH₂)-9-Fluorene·HCl)

The title compound was prepared from the DF-diastereomer of Example 149 by the method of Example 6.

NMR shift of the (D)Ala methyl=1.12δ (DMSOd₆).

Optical rotation [α]_(D) -20.9°; -34.5° (365) MeOH.

Analysis calcd. for C₂₉ H₃₃ N₃ O₃ ·HCl·11/4H₂ O (MW=530.58): C, 65.65; H, 6.93; N, 7.92; Cl, 6.68. Found: C, 65.50; H, 6.54; N, 7.78; Cl, 6.48.

EXAMPLE 151 2,6-dimethyl-L-tyrosyl-N-[2-(9H-fluoren-9-yl)ethyl]-D-alaninamide, hydrochloride UF isomer ##STR160##

The title compound was prepared from the UF-diastereomer of Example 149 by the method of Example 6.

NMR shift of the (D)ala methyl=0.89δ (DMSOd₆).

Optical rotation [α]_(D) +127.7°; +424.7° (365) MeOH.

Analysis calcd. for C₂₉ H₃₃ N₃ O₃ ·11/8HCl·1/4H₂ O (MW=517.12): C, 67.36; H, 6.75; N, 8.13; Cl, 7.71. Found: C, 67.13; H, 6.57; N, 8.15; Cl, 7.41.

EXAMPLE 152 (3-bromo-1-propynyl)benzene ##STR161##

The 1-phenylpropargyl bromide was prepared by adding phosphorous tribromide (46.7 g, 172.5 mmol) dropwise to a stirred solution of 1-phenylpropargyl alcohol (60 g, 450 mmol) in anhydrous Et₂ O (300 ml). The reaction mixture was heated for 2 h at reflex; and then poured onto ice. The organic layer was separated, dried over MgSO₄ and stripped of solvent to obtain the product oil. This material was used without further purification.

EXAMPLE 153 2-(3-phenyl-2-propynyl)-1H-isoindole-1,3(2H)-dione ##STR162##

The title compound was prepared by stirring a mixture of the product (450 mmol) from Example 152 and potassium phthalimide (83 g, 450 mmol) in dimethylformamide (DMF, 600 ml) for 16 h. The reaction mixture was poured into water and the resulting solid was filtered off. This title compound was washed with H₂ O and Et₂ O before being dried under vacuum. The product (107 g) was used without further purification.

EXAMPLE 154 3-phenyl-2-propyn-1-amine ##STR163##

The title product was prepared from the product of Example 153 using the method of Example 48.

EXAMPLE 155 1,1-dimethylethyl [1R-methyl-2-oxo-2-[(3-phenyl-2-propynyl)amino]ethyl]carbamate ##STR164## (Boc-(D)Ala-NHCH₂ C.tbd.CPh)

The title compound was prepared from the product of Example 154 by the method of Example 1 using one equivalent less of NMM. NMR shift of the (D)Ala methyl=1.39δ (CDCl₃).

EXAMPLE 156 αR-amino-N-(3-phenyl-2-propynyl)propanamide, monohydrochloride ##STR165## ((D)Ala-NHCH₂ C.tbd.CPh·HCl)

The title compound was prepared from the title compound of Example 155 by the method of Example 2.

NMR shift of the (D)Ala methyl=1.40δ (DMSOd₆).

Optical rotation [α]_(D) -9.3°; -22.3° (365) MeOH.

Analysis calcd. for C₁₂ H₁₄ N₂ O·HCl·9/16H₂ O (MW=248.85): C, 57.92; H, 6.53; N, 11.26; Cl, 14.25. Found: C, 57.60; H, 6.27; N, 11.36; Cl, 14.61.

The free base of the title compound was formed and isolated by the method of Example 44.

EXAMPLE 157 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-(3-phenyl-2-propynyl)-D-alaninamide ##STR166## (Boc-(DL)2,6Me₂ Tyr-(D)Ala-NHCH₂ C.tbd.CPh)

The title mixture of diastereomers was prepared from the free base of the title product of Example 156 by the method of Example 45. The diastereomers were separated by PLC on Woelm® silica eluting with 2.5/97.3/0.2; MeOH/CHCl₃ /NH₄ OH.

Diastereomer DF:

NMR shift of the (D)Ala methyl=1.21δ (DMSOd₆).

Diastereomer UF:

NMR shift of the (D)Ala methyl=1.03δ (DMSOd₆).

EXAMPLE 158 2,6-dimethyl-D-tyrosyl-N-(3-phenyl-2-propynyl)-D-alaninamide, hydrochloride DF isomer ##STR167## (2,6Me₂ -D-Tyr-(D)Ala-NHCH₂ C.tbd.CPh·HCl)

The title compound was prepared from the DF-diastereomer of Example 157 by the method of Example 6.

NMR shift of the (D)Ala methyl=1.25δ (DMSOd₆).

Optical rotation [α]_(D) -58.5°; -218.5° (365) MeOH.

Analysis calcd. for C₂₃ H₂₇ N₃ O₃ ·11/8HCl·17/8H₂ O (MW=450.27): C, 61.35; H, 6.69; N, 9.33; Cl, 8.86. Found: C, 61.36; H, 6.37; N, 9.24; Cl, 8.68.

EXAMPLE 159 2,6-dimethyl-L-tyrosyl-N-(3-phenyl-2-propynyl)-D-alaninamide, monohydrochloride UF isomer ##STR168## (2,6Me₂ Tyr-(D)Ala-NHCH₂ C.tbd.CPh·HCl)

The title compound was prepared from the UF-diastereomer of Example 157 by the method of Example 6.

NMR shift of the (D)Ala methyl=0.88δ (DMSOd₆).

Optical rotation [α]_(D) +90.2°; +352.6° (365) MeOH.

Analysis calcd. for C₂₃ H₂₇ N₃ O₃ ·HCl·H₂ O (MW=447.91): C, 61.67; H, 6.75; N, 9.38; Cl, 7.91. Found: C, 61.84; H, 6.36; N, 9.26; Cl, 8.22.

EXAMPLE 160 2-(3-phenyl-2Z-propenyl)-1H-isoindole-1,3(2H)-dione ##STR169##

The title compound was prepared from the title product (15 g, 57.4 mmol) of Example 153 by hydrogenation using Lindlar catalyst (2.25 g) and quinoline (0.79 g, 6.09 mmol) in THF (150 ml). The reaction mixture was hydrogenated at 5 psi and 0° to obtain a quantitative yield of the cis product.

NMR: CH₂ =4.51δ, 2H; vinyl=5.40 to 5.58δ, H, 6.45 to 5.80δ1H.

EXAMPLE 161 3-phenyl-2Z-propen-1-amine ##STR170##

The title compound was prepared from the product of Example 160 using the method of Example 48.

EXAMPLE 162 1,1-dimethylethyl [1R-methyl-2-oxo-2-[(3-phenyl-2Z-propenyl)amino]ethyl]carbamate ##STR171## (Boc-(D)Ala-NHCH₂ -(cis-CH═CH)ph)

The title compound was prepared from the product of Example 161 by the method of Example 1 using one equivalent less of NMM. The title compound was purified by PLC on Woelm® silica eluting with 12% EtOAc/CH₂ Cl₂.

NMR shift of the (D)Ala methyl=1.32δ (CDCl₃).

EXAMPLE 163 αR-amino-N-(3-phenyl-2Z-propenyl)propanamide ##STR172## ((D)Ala-NHCH₂ (cis-CH═CH)ph)

The title compound was prepared from the product of Example 162 by the method of Example 2. The free base was formed and isolated by the method of Example 44.

EXAMPLE 164 N-[(1,1-dimethylethoxy)carbonyl]-2,6-dimethyl-DL-tyrosyl-N-(3-phenyl-2Z-propenyl)-D-alaninamide ##STR173## (Boc-(DL)2,6Me₂ Tyr-(D)Ala-NHCH₂ (cis-CH═CH)Ph)

The title mixture of disastereomers was prepared from the title product of Example 163 by the method of Example 45. The diastereomers were separated by PLC on Woelm® silica using a gradient elution from 1% to 4% MeOH/CH₂ Cl₂.

Diastereomer DF:

NMR shift of the (D)Ala methyl=1.19δ (DMSOd₆).

Diastereomer UF:

NMR shift of the (D)Ala methyl=1.00δ (DMSOd₆).

EXAMPLE 165 2,6-dimethyl-D-tyrosyl-N-(3-phenyl-2Z-propenyl)-D-alaninamide, hydrochloride DF isomer ##STR174## (2,6Me₂ Tyr-(D)Ala-NHCH₂ (cis-CH═CH)Ph·HCl)

The title compound was prepared from the DF-diastereomer of Example 164 by the method of Example 6.

NMR shift of the (D)Ala methyl=1.15δ (DMSOd₆).

Optical rotation [α]_(D) -65.6°; -288.2° (365) MeOH.

Analysis calcd. for C₂₃ H₂₉ N₃ O₃ ·1 1/16HCl·3/4H₂ O (MW=447.75): C, 61.70; H, 7.11; N, 9.38; Cl, 8.41. Found: C, 61.71; H, 6.74; N, 9.31; Cl, 8.52.

EXAMPLE 166 2,6-dimethyl-L-tyrosyl-N-(3-phenyl-2Z-propenyl)-D-alaninamide, hydrochloride UF isomer ##STR175## (2,6Me₂ Tyr-(D)Ala-NHCH₂ (cis-CH═CH)Ph·HCl)

The title compound was prepared from the UF-diastereomer of Example 164 by the method of Example 6.

NMR shift of the (D)Ala methyl=0.89δ (DMSOd₆).

Optical rotation [α]_(D) +114.9°, +402.6° (365) MeOH.

Analysis calcd. for C₂₃ H₂₉ N₃ O₃ ·1 1/16HCl·1/2H₂ O (MW=443.25): C, 62.32; H, 7.06; N, 9.48; Cl, 8.50. Found: C, 62.35; H, 6.83; N, 9.72; Cl, 8.53.

EXAMPLE 167

Preparation of ##STR176##

The title product was prepared by the method of Example 135 substituting ethyl 4-bromobenzoate for the 1-fluoro-4-iodobenzene and in addition adding 413 mg tri-o-tolyl phosphene.

The reaction mixture was partitioned in DMF at 90° and filtered. The filtrate was cooled to 0° and filtered. The product was dried under vacuum.

Analysis calcd. for C₂₀ H₁₇ NO₄ (MW=335.36): C, 71.27; H, 4.91; N, 4.24. Found: C, 71.63; H, 5.11; N, 4.18.

EXAMPLE 168 ##STR177##

The product of Example 167 (23.00 g, 0.686 moles) and sodium borohydride was suspended in a solution of 614 ml of 2-propanol and 104 ml of water. Glacial acetic acid (71.8 ml, 1.25 moles) was added dropwise cautiously at first. The mixture was heated at reflux for 2 h. The solvent was removed under vacuum and the residue partitioned in water and CH₂ Cl₂. The aqueous layer was separated, washed twice with CH₂ Cl₂, and then rendered alkaline with potassium carbonate. The resultant oil was extracted with CH₂ Cl₂, dried over Na₂ SO₄ and concentrated under vacuum. The title compound (7.8 g) was used without further purification.

EXAMPLE 169 (Z-(D)Ala-NHCH₂ CH═CH(4-CO₂ Et)Ph) ##STR178##

The title compound was prepared from the product of Example 168 using the method of Example 8. The title compound was purified by PLC on Porasil eluting with 1 to 2% MeOH/CH₂ Cl₂. NMR shift of the (D)Ala methyl=1.39δ (CDCl₃).

EXAMPLE 170 ((D)Ala-NH(CH₂)₃ (4-CO₂ Et)Ph) ##STR179##

The title compound was prepare by hydrogenation of the product of Example 169 using the method of Example 121. NMR shift of the (D)Ala methyl=1.31δ (CDCl₃).

EXAMPLE 171 (Boc-(DL)2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ (4-CO₂ Et)Ph) ##STR180##

The title diastereomers were prepared by the method of Example 45 using the product of Example 170 and substituting DMF for the CH₂ Cl₂. The diastereomers were separated by PLC on Merck silica eluting with a 3/7: MeOH/CHCl₃ solution containing 0.1% NH₄ OH.

Diastereomer DF:

NMR shift of the (D)Ala methyl=0.99δ

Diastereomer UF:

NMR shift of the (D)Ala methyl=1.18δ

EXAMPLE 172 2,6-dimethyltyrosyl-N-[3-(4-ethoxycarbonylphenyl)propyl]-D-alaninamide, hydrochloride ##STR181## (2,6Me₂ tyr-(D)Ala-NH(CH₂)₃ (4-CO₂ Et)Ph·HCl

The title compound was prepared from the DF-diastereomer of Example 171 by the method of Example 6.

NMR shift of (D)Ala methyl=1.15δ (DMSOd₆)

Optical rotation [α]_(D) -64.4°; -239.0° MeOH.

Analysis Calcd. for C₂₆ H₃₅ N₃ O₅ ·HCl·1/2H₂ O (MW=515.05): C, 60.63; H, 7.24; N, 8.16; Cl, 6.88. Found: C, 60.60; H, 6.94; N, 8.05; Cl, 6.86.

EXAMPLE 173 ##STR182##

The title compound was prepared using the method of Example 135 substituting 4-iodobenzamide for the 1-fluoro-4-iodo-benzene.

EXAMPLE 174 ##STR183##

The title compound was prepared from the product of Example 173 using the method of Example 48. It was necessary to purify the product further by adding 4 equivalents of 3% NaOH and extracting this with CH₂ Cl₂ using a liquid-liquid extractor for 24 hours. The solvent was removed in vacuo from the organic extract and the resultant solid was used without further purification.

EXAMPLE 175 (Z-(D)Ala-NH(CH₂)₃ (4-CONH₂)Ph) ##STR184##

The title compound was prepared by the method of Example 8 using the product of Example 174 in place of NH₂ Ad·HCl and using one equivalent less of NMM. The reaction mixture was filtered and the filtrate was diluted with water to obtain the solid product. This was filtered, washed with water on the funnel and dried under vacuum. The product was used without further purification.

EXAMPLE 176 ((D)Ala-NH(CH₂)₃ (4-CONH₂)Ph) ##STR185##

The title compound was prepared by the method of Example 9 substituting the product of Example 175 for the product of Example 8.

EXAMPLE 177 (Boc(DL)2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ (4-CONH₂)Ph) ##STR186##

The title diastereomers were prepared by the method of Example 45 using the product of Example 176 and substituting DMF for the CH₂ Cl₂.

The reaction mixture was filtered and the filtrate was partitioned in EtOAc and 0.5N KHSO₄ solution. The organic layer was separated and washed successively with a 0.5N KHSO₄ solution and brine at which point the DF diastereomer precipitated from the organic solution. This was filtered off, triturated with MeOH and used without further purification. The mother liquors were stripped under reduced pressure. The residue, containing mainly the UF diastereomer after was purified further by LPC on Woelm Silica eluting with 20% isopropanol/methyl t-butyl ether with 0.1% NH₄ OH.

Diastereomer DF

NMR shift of the (D)Ala methyl-1.18δ (DMSOd₆).

Diastereomer UF

NMR shift of the (D)Ala methyl=0.99δ (DMSOd₆)

EXAMPLE 178 2,6-dimethyl-D-tyrosyl-N-[3-(4-aminocarbonylphenyl)propyl]-D-alaninamide, hydrochloride DF isomer ##STR187## (2,6Me₂ Tyr-(D)Ala-NH(CH₂)₃ (4-CONH₂)Ph·HCl)

The title compound was prepared from the DF diastereomer of Example 177 by the method of Example 6.

NMR shift of (D)Ala methyl=1.16δ (DMSOd₆).

Optical rotation [α].sub.Δ -78.0°; 229.3°(365) MeOH.

Analysis Calcd. for C₂₄ H₃₂ N₄ O₄ ·HCl·1 1/8H₂ O (MW=497.27): C, 57.97; H, 7.15; N, 11.27; Cl, 7.13. Found: C, 57.75; H, 6.75; N, 11.02; Cl, 7.22.

EXAMPLE 179 (Z-(DL)2,6Me₂ Tyr) ##STR188##

(DL)2,6-dimethyltyrosine hydrochloride (20.0 g) was dissolved in 1 liter of water. The pH was adjusted to 8.5 (10% NaOH in H₂ O) and benzyl chloroformate (14.3 g) was added in one portion. The pH was maintained between 7 and 8 with the aqueous NaOH for 2 hours. The reaction mixture was then acidified (conc. HCl) and extracted with ethyl acetate. The aqueous layer was saturated with NaCl, and then extracted twice with ethyl acetate. The organic fractions were combined, dried (Na₂ SO₄), filtered, and stripped to an oil. This oil was triturated with ether/hexane, giving a solid. The solid was ground up and dried overnight at 42° C. and 110 torr.

EXAMPLE 180 (Z-(DL)2,6Me₂ Tyr-(D)Ala-NH(CH₂)Ph) ##STR189##

The title diastereomers were prepared by the method of Example 45 using D-alanylphenylpropylamide as the C-terminal unit and substituting the product of Example 179 for the t-butoxycarbonyl-2-6-dimethyltyrosine and DMF for the CH₂ Cl₂. The diastereomers were separated by gradient PLC on silica gel eluting with 1.5 to 5% MeOH/CHCl₃.

Diastereomer DF:

NMR shift of the (D)Ala methyl=1.20δ (DMSOd₆).

Diastereomer UF:

NMR shift of the (D)Ala methyl=1.00δ (DMSOd₆).

EXAMPLE 181 ##STR190## (Z-2,6Me₂ Tyr(OAc)-CD)Ala-NH(CH₂)₃ Ph)

The UF diastereomer of the title product from Example 180 (3.85 g, 0.00724 moles) was dissolved in 300 ml of acetonitrile and triethylamine (0.00836 moles, 0.85 g). Acetylchloride (0.00836 moles, 6.56 g) was added dropwise to the stirred mixture while maintaining the reaction temperature at 25°. The reaction was stirred until no starting material was present as determined by TLC. The reaction mixture was partitioned between CH₂ Cl₂ and sufficient 5% KHSO₄ solution to render the mixture acidic. The organic layer was separated, washed once with 5% KHSO₄ solution and once with brine. After drying over anhydrous. Na₂ SO₄, the solvent was removed under vacuum. The white solid (3.86 g) was used without further purification.

NMR shift of (D)Ala methyl=0.97δ (DMSOd₆).

Analysis calcd. for C₃₃ H₃₉ N₃ O₆ (MW=573.69): Calc.: C, 69.09; H, 6.85; N, 7.32. Found: C, 68.93; H, 6.81; N, 7.33.

EXAMPLE 182 2,6-dimethyl-O[methylcarbonyl]-L-tyrosyl-N-(3-phenylpropyl)-D-alaninamide, hydrochloride ##STR191## (2,6Me₂ Tyr(OAc)-(D)Ala-NH(CH₂)₃ Ph)

The title material was prepared as described in Example 9 using the title product of Example 181 substituting glacial acetic acid for the methanol. The product was dried under vacuum over NaOH for 5 days. Optical rotation [α]_(D) +96.1; +327.9 (365) MeOH.

NMR shift for (D)Ala methyl=1.03δ (DMSOd₆).

Analysis calcd. for C₂₅ H₃₃ N₃ O₄ ·13/8H₂ O (MW=464.33): Calc.: C, 64.67; H, 7.76; N, 9.05. Found: C, 64.69; H, 7.37; N, 8.68.

EXAMPLE 183 Analgesic Properties of the Substituted Dipeptide Amides.

The receptor binding and biological properties of the following compounds of this invention are illustrated in Table 1 utilizing the previously described opiate binding and writhing assay. The standard screening dose for the writhing assay was 10 mg/kg s.c. and p.o. The standard screening dose for the opiate binding assay was 10⁻⁵ molar.

                  TABLE 1                                                          ______________________________________                                         ANALGESIC PROPERTIES                                                                    Opiate.sup.a                                                                              Writhing Mouse.sup.b                                       Example    Binding      Subc.      Oral                                        ______________________________________                                         5          1.0 × 10.sup.-5                                                                       Inactive   Inactive                                    7          1.0 × 10.sup.-6                                                                       Inactive   Inactive                                    20         Inactive     Active     Inactive                                    21         Inactive     Active     Inactive                                    24         8.6 × 10.sup.-7                                                                       Lethal     Inactive                                    25         8.0 × 10.sup.-5                                                                       Inactive   Inactive                                    29         4.9 × 10.sup.-6                                                                       Inactive   Inactive                                    30         6.1 × 10.sup.-8                                                                       Inactive   Inactive                                    32         Inactive     Inactive   Active                                      35         1.4 × 10.sup.-8                                                                       Active     Active                                      37         1.4 × 10.sup.-6                                                                       Inactive   Inactive                                    39         1.2 × 10.sup.-9                                                                       Inactive   Inactive                                    44         Inactive     Active     Active                                      46         2.2 × 10.sup.-7                                                                       Inactive   Inactive                                    47         2.9 × 10.sup.-9                                                                       Active     Active                                      52         1.3 × 10.sup.-8                                                                       Active     Inactive                                    58         1.0 × 10.sup.-9                                                                       Active     Inactive                                    60         3.6 × 10.sup.-5                                                                       Active     Active                                      68         1.1 × 10.sup.-9                                                                       Active     Inactive                                    73         3.0 × 10.sup.-10                                                                      Active     Inactive                                    85         --           Active     Inactive                                    108        8.2 × 10.sup.-9                                                                       Active     Inactive                                    109        4.0 × 10.sup.-10                                                                      Active     Inactive                                    115        8.7 × 10.sup.-9                                                                       Active     Active                                      ______________________________________                                          .sup.a = IC.sub.50 expressed as moles/liter                                    .sup.b = Active refers to the effect of the screening dose (10 mg/kg).    

What is claimed is:
 1. A compound of the formula: ##STR192## or a pharmaceutically acceptable acid addition salt thereof: wherein R¹ is hydrogen, lower alkyl, hydroxy, lower alkoxy, --OCO₂ -lower alkyl, O(CH₂)_(m) -phenyl with the phenyl optionally substituted by a member of the group comprising halogen, --NO₂, --CN, --NH₂, or lower alkyl;wherein m is an integer from 1 to 4; wherein R² and R³ represent lower alkyl, halogen or lower alkoxy, or either one of R² or R³ is hydrogen and the other is lower alkyl, halogen or lower alkoxy; wherein R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ may be the same or different and represent hydrogen or lower alkyl; wherein R¹⁰ is selected from the group consisting of

    --(ALK)X

wherein ALK represents alkylene, thioalkylene, or oxyalkylene having 1 to 5 carbon atoms; alkenylene or alkynylene having 2 to 4 carbon atoms; and wherein X represents 2-thienyl or 3-thienyl with the proviso that X may represent 3-thienyl only when ALK is not alkylene; wherein V represents an asymmetric carbon atom that may be racemic or have the D or L configuration; and wherein W represents an asymmetric carbon atom when R⁷ and R⁸ are not the same which may be racemic or have the D or L configuration.
 2. A compound of the formula: ##STR193## or a pharmaceutically acceptable addition salt thereof wherein R¹⁰ is selected from the group consisting of

    --(ALK)X

wherein ALK represents alkylene, thioalkylene, or oxyalkylene, having 1 to 4 carbon atoms; alkenylene or alkynylene having 2 to 4 carbon atoms; and wherein X is 2-thienyl or 3-thienyl with the proviso that X can only be 3-thienyl when ALK is not alkylene; wherein V and W represent asymmetric carbon atoms that may independently be racemic or have the D and L configuration.
 3. A compound according to claim 2 which is 2,6-dimethyl-L-tyrosyl-N-[2-(2-thienyl)ethyl]-D-alaninamide, hydrochloride.
 4. A compound according to claim 2 which is 2,6-dimethyltyrosyl-N-[3-(2-thienyl)propyl-D-alaninamide, hydrochloride and the diastereomers thereof.
 5. A compound according to claim 2, which is 2,6-dimethyltyrosyl-N-[3-(2-thienyl)-2E-propenyl]-D-alaninamide, hydrochloride, and the diastereomers thereof.
 6. A compound according to claim 2, which is 2,6-dimethyltyrosyl-N-[3-(3-thienyl)-2E-propenyl]-D-alaninamide, hydrochloride, and the diastereomers thereof.
 7. A pharmaceutical composition for treating pain in mammals comprising a therapeutically effective amount of a compound according to claim 1 in a pharmaceutically acceptable carrier.
 8. A method for treating pain in mammals comprising administering a therapeutically effective amount of a compound according to claim 1 to a mammal in need of such treatment. 